PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34710250-9	2022	Low doses of etoposide combined with the PARP5B inhibitor XAV939 induced senescence and apoptosis in human SCC lines.	XAV939	58-64	tankyrase 2	Homo sapiens	41-47
34878149-7	2022	XAV939 treatment, CCK-8, 5-ethynyl-2"-deoxyuridine (EdU) staining, wound healing and Transwell assays were performed to investigate the signaling pathways involved in the biological activity of CtBP2 in ECA109 cells.	XAV939	0-6	C-terminal binding protein 2	Homo sapiens	194-199
34586448-9	2022	Conversely, when XAV939, an inhibitor of the Wnt/beta-catenin signaling pathway, was added to YAP knockdown pSDSCs a higher self-renewal ability resulted.	XAV939	17-23	catenin beta 1	Homo sapiens	49-61
34586448-9	2022	Conversely, when XAV939, an inhibitor of the Wnt/beta-catenin signaling pathway, was added to YAP knockdown pSDSCs a higher self-renewal ability resulted.	XAV939	17-23	Yes1 associated transcriptional regulator	Homo sapiens	94-97
34710250-9	2022	Low doses of etoposide combined with the PARP5B inhibitor XAV939 induced senescence and apoptosis in human SCC lines.	XAV939	58-64	serpin family B member 3	Homo sapiens	107-110
34710250-10	2022	NBS1 overexpression in these cells inhibited the effects of low-dose etoposide/XAV939 treatment.	XAV939	79-85	nibrin	Homo sapiens	0-4
34942044-12	2021	While an inhibitor of Wnt/ beta-catenin pathway, XAV-939, could reverse the effect caused by daidzein.	XAV939	49-56	catenin beta 1	Homo sapiens	27-39
34686198-8	2021	This pro-fibrotic effect of WEE1 was significantly decreased by treatment with the Wnt/beta-catenin inhibitor XAV939, suggesting that WEE1 acts via the Wnt/beta-catenin signaling pathway.	XAV939	110-116	WEE 1 homolog 1 (S. pombe)	Mus musculus	28-32
34887359-13	2021	Silencing beta-catenin by sh-beta-catenin or XAV-939 exacerbated UVB irradiation-mediated cell senescence, apoptosis, and ROS production in HaCaT cells, which was ameliorated by Art treatment.	XAV939	45-52	catenin beta 1	Homo sapiens	10-22
34889158-9	2021	Mechanically, blocking of Wnt/beta-catenin pathway by XAV939 reversed the promotion effect of INHBA overexpression on breast cancer cells" proliferation, migration and invasion.	XAV939	54-60	catenin beta 1	Homo sapiens	30-42
34889158-9	2021	Mechanically, blocking of Wnt/beta-catenin pathway by XAV939 reversed the promotion effect of INHBA overexpression on breast cancer cells" proliferation, migration and invasion.	XAV939	54-60	inhibin subunit beta A	Homo sapiens	94-99
34672248-12	2021	Finally, use of XAV939 (Wnt pathway inhibitor) downregulated osteogenic differentiation in miR-15a5p/PDCD4/Wnt-dependent signaling pathway.	XAV939	16-22	programmed cell death 4	Mus musculus	101-106
34101073-7	2021	Importantly, the combination of XAV939 (an inhibitor of Wnt/beta-catenin) promoted the actions of (Ac)5GP on TNF-alpha-induced migration, invasion, and inflammation, further revealing the involvement of Wnt/beta-catenin pathway underlying the therapeutic effects of (Ac)5GP on TNF-alpha-stimulated MH7A.	XAV939	32-38	Wnt family member 1	Rattus norvegicus	56-59
34101073-7	2021	Importantly, the combination of XAV939 (an inhibitor of Wnt/beta-catenin) promoted the actions of (Ac)5GP on TNF-alpha-induced migration, invasion, and inflammation, further revealing the involvement of Wnt/beta-catenin pathway underlying the therapeutic effects of (Ac)5GP on TNF-alpha-stimulated MH7A.	XAV939	32-38	catenin beta 1	Homo sapiens	60-72
34765592-0	2021	Ocular Wnt/beta-Catenin Pathway Inhibitor XAV939-Loaded Liposomes for Treating Alkali-Burned Corneal Wound and Neovascularization.	XAV939	42-48	catenin (cadherin associated protein), beta 1	Mus musculus	11-23
34765592-3	2021	In this study, we constructed a Wnt/beta-catenin pathway inhibitor, XAV939-loaded liposome (XAV939 NPs), and revealed its anti-inflammatory and antiangiogenic effects.	XAV939	68-74	catenin (cadherin associated protein), beta 1	Mus musculus	36-48
34863303-9	2021	When we used Wnt inhibitor XAV939 to treat hDPSCs transfected with wild-type SATB2 plasmid, the increased odontogenic differentiation capacity was attenuated.	XAV939	27-33	SATB homeobox 2	Homo sapiens	77-82
34587869-3	2021	In addition, by adding xav939, a typical inhibitor of Wnt/beta-catenin signaling pathway, the regulatory function of Wnt/beta-catenin signaling was clarified.	XAV939	23-29	catenin (cadherin associated protein), beta 1	Mus musculus	58-70
34587869-3	2021	In addition, by adding xav939, a typical inhibitor of Wnt/beta-catenin signaling pathway, the regulatory function of Wnt/beta-catenin signaling was clarified.	XAV939	23-29	catenin (cadherin associated protein), beta 1	Mus musculus	121-133
34101073-7	2021	Importantly, the combination of XAV939 (an inhibitor of Wnt/beta-catenin) promoted the actions of (Ac)5GP on TNF-alpha-induced migration, invasion, and inflammation, further revealing the involvement of Wnt/beta-catenin pathway underlying the therapeutic effects of (Ac)5GP on TNF-alpha-stimulated MH7A.	XAV939	32-38	tumor necrosis factor	Homo sapiens	109-118
34101073-7	2021	Importantly, the combination of XAV939 (an inhibitor of Wnt/beta-catenin) promoted the actions of (Ac)5GP on TNF-alpha-induced migration, invasion, and inflammation, further revealing the involvement of Wnt/beta-catenin pathway underlying the therapeutic effects of (Ac)5GP on TNF-alpha-stimulated MH7A.	XAV939	32-38	Wnt family member 1	Rattus norvegicus	203-206
34101073-7	2021	Importantly, the combination of XAV939 (an inhibitor of Wnt/beta-catenin) promoted the actions of (Ac)5GP on TNF-alpha-induced migration, invasion, and inflammation, further revealing the involvement of Wnt/beta-catenin pathway underlying the therapeutic effects of (Ac)5GP on TNF-alpha-stimulated MH7A.	XAV939	32-38	catenin beta 1	Homo sapiens	207-219
34101073-7	2021	Importantly, the combination of XAV939 (an inhibitor of Wnt/beta-catenin) promoted the actions of (Ac)5GP on TNF-alpha-induced migration, invasion, and inflammation, further revealing the involvement of Wnt/beta-catenin pathway underlying the therapeutic effects of (Ac)5GP on TNF-alpha-stimulated MH7A.	XAV939	32-38	tumor necrosis factor	Homo sapiens	277-286
34852024-11	2021	Besides, pharmacological inhibition of Wnt/beta-catenin signaling by XAV-939 abrogated the effects of SFRP2 knockdown on cancer stemness and radioresistance of glioma cells.	XAV939	69-76	catenin beta 1	Homo sapiens	43-55
34852024-11	2021	Besides, pharmacological inhibition of Wnt/beta-catenin signaling by XAV-939 abrogated the effects of SFRP2 knockdown on cancer stemness and radioresistance of glioma cells.	XAV939	69-76	secreted frizzled related protein 2	Homo sapiens	102-107
34686198-8	2021	This pro-fibrotic effect of WEE1 was significantly decreased by treatment with the Wnt/beta-catenin inhibitor XAV939, suggesting that WEE1 acts via the Wnt/beta-catenin signaling pathway.	XAV939	110-116	catenin beta 1	Homo sapiens	87-99
34686198-8	2021	This pro-fibrotic effect of WEE1 was significantly decreased by treatment with the Wnt/beta-catenin inhibitor XAV939, suggesting that WEE1 acts via the Wnt/beta-catenin signaling pathway.	XAV939	110-116	WEE 1 homolog 1 (S. pombe)	Mus musculus	134-138
34686198-8	2021	This pro-fibrotic effect of WEE1 was significantly decreased by treatment with the Wnt/beta-catenin inhibitor XAV939, suggesting that WEE1 acts via the Wnt/beta-catenin signaling pathway.	XAV939	110-116	catenin beta 1	Homo sapiens	156-168
34657141-19	2021	The inhibition of Wnt/beta-catenin signaling pathway by XAV-939 weakened RMRP-mediated TMZ resistance in glioma cells.	XAV939	56-63	catenin beta 1	Homo sapiens	22-34
34657141-19	2021	The inhibition of Wnt/beta-catenin signaling pathway by XAV-939 weakened RMRP-mediated TMZ resistance in glioma cells.	XAV939	56-63	RNA component of mitochondrial RNA processing endoribonuclease	Homo sapiens	73-77
34553072-8	2021	Further investigation showed that blocking the Wnt/beta-catenin signaling pathway by XAV-939 reversed the effects of WDR74 on cell proliferation, migration, and invasion in HCT116 cells.	XAV939	85-92	catenin beta 1	Homo sapiens	51-63
34466147-17	2021	XAV939 attenuated the effect of BCYRN1 overexpression on HTR-8/SVneo cells.	XAV939	0-6	brain cytoplasmic RNA 1	Homo sapiens	32-38
34365704-7	2021	XAV939, which was a small molecule inhibitor, was used to inhibit the Wnt/beta-catenin pathway.	XAV939	0-6	catenin beta 1	Rattus norvegicus	74-86
34365704-13	2021	Exogenous administration of XAV939 suppressed the promoting effect of SCs -derived exosomes on DRG cells and the expression of downstream proteins of Wnt/beta-catenin pathway in DRG cells was also suppressed.	XAV939	28-34	catenin beta 1	Rattus norvegicus	154-166
34466147-15	2021	Cells overexpressing BCYRN1 were further treated with the Wnt pathway inhibitor XAV939.	XAV939	80-86	brain cytoplasmic RNA 1	Homo sapiens	21-27
34466147-15	2021	Cells overexpressing BCYRN1 were further treated with the Wnt pathway inhibitor XAV939.	XAV939	80-86	Wnt family member 1	Homo sapiens	58-61
34553072-8	2021	Further investigation showed that blocking the Wnt/beta-catenin signaling pathway by XAV-939 reversed the effects of WDR74 on cell proliferation, migration, and invasion in HCT116 cells.	XAV939	85-92	WD repeat domain 74	Homo sapiens	117-122
34511958-10	2021	Moreover, zebrafish was treated with XAV-939, an inhibitor of the Wnt/beta-catenin pathway.	XAV939	37-44	catenin (cadherin-associated protein), beta 1	Danio rerio	70-82
34511958-16	2021	In zebrafish, the mean percentage area of melanin granules and the expression of beta-catenin, lef1, tyr and mitf were decreased after treated with XAV-939.	XAV939	148-155	catenin (cadherin-associated protein), beta 1	Danio rerio	81-93
34511958-16	2021	In zebrafish, the mean percentage area of melanin granules and the expression of beta-catenin, lef1, tyr and mitf were decreased after treated with XAV-939.	XAV939	148-155	lymphoid enhancer-binding factor 1	Danio rerio	95-99
34511958-16	2021	In zebrafish, the mean percentage area of melanin granules and the expression of beta-catenin, lef1, tyr and mitf were decreased after treated with XAV-939.	XAV939	148-155	tyrosinase	Danio rerio	101-104
34511958-16	2021	In zebrafish, the mean percentage area of melanin granules and the expression of beta-catenin, lef1, tyr and mitf were decreased after treated with XAV-939.	XAV939	148-155	melanocyte inducing transcription factor a	Danio rerio	109-113
34659522-9	2021	XAV-939 reversed the activation of Wnt signaling and EMT induced by FAM83A.	XAV939	0-7	family with sequence similarity 83 member A	Homo sapiens	68-74
34421534-4	2021	Here, we investigated the effects of the glycogen synthase kinase-3beta inhibitor CHIR99021, which upregulates beta-catenin agonizing Wnt; and the tankyrase-1/2 inhibitor XAV939, which downregulates beta-catenin antagonizing Wnt.	XAV939	171-177	tankyrase	Homo sapiens	147-160
34421534-4	2021	Here, we investigated the effects of the glycogen synthase kinase-3beta inhibitor CHIR99021, which upregulates beta-catenin agonizing Wnt; and the tankyrase-1/2 inhibitor XAV939, which downregulates beta-catenin antagonizing Wnt.	XAV939	171-177	catenin beta 1	Homo sapiens	199-211
34367279-14	2021	XAV939 could enhance these phenomena induced by irradiation combined with SPP1 knockdown.	XAV939	0-6	secreted phosphoprotein 1	Homo sapiens	74-78
35397630-8	2022	In APP mice, SV benefits were recapitulated by treatment with the Wnt/beta-catenin specific agonist WAY-262611, whereas they were fully abolished in mice that received the Wnt/beta-catenin pathway inhibitor XAV939 during the last month of SV treatment.	XAV939	207-213	catenin (cadherin associated protein), beta 1	Mus musculus	176-188
34488598-9	2021	The expression level of LRP1 and RAGE was detected in cultured microvessels after using Wnt inhibitor DKK-1 and beta-catenin inhibitor XAV-939.	XAV939	135-142	low density lipoprotein receptor-related protein 1	Mus musculus	24-28
34488598-9	2021	The expression level of LRP1 and RAGE was detected in cultured microvessels after using Wnt inhibitor DKK-1 and beta-catenin inhibitor XAV-939.	XAV939	135-142	advanced glycosylation end product-specific receptor	Mus musculus	33-37
34488598-9	2021	The expression level of LRP1 and RAGE was detected in cultured microvessels after using Wnt inhibitor DKK-1 and beta-catenin inhibitor XAV-939.	XAV939	135-142	catenin (cadherin associated protein), beta 1	Mus musculus	112-124
35589066-10	2022	Suppression of Wnt/beta-catenin signaling with XAV-939 promoted SFRP3 and SFRP4 expression and rescued mechanical stress-induced cartilage degeneration in vivo and in vitro.	XAV939	47-54	catenin beta 1	Homo sapiens	19-31
35589066-10	2022	Suppression of Wnt/beta-catenin signaling with XAV-939 promoted SFRP3 and SFRP4 expression and rescued mechanical stress-induced cartilage degeneration in vivo and in vitro.	XAV939	47-54	frizzled related protein	Homo sapiens	64-69
35589066-10	2022	Suppression of Wnt/beta-catenin signaling with XAV-939 promoted SFRP3 and SFRP4 expression and rescued mechanical stress-induced cartilage degeneration in vivo and in vitro.	XAV939	47-54	secreted frizzled related protein 4	Homo sapiens	74-79
35452660-7	2022	XAV-939 was used as an inhibitor of the Wnt/beta-catenin pathway.	XAV939	0-7	wingless-type MMTV integration site family, member 3A	Mus musculus	40-43
35452660-7	2022	XAV-939 was used as an inhibitor of the Wnt/beta-catenin pathway.	XAV939	0-7	catenin (cadherin associated protein), beta 1	Mus musculus	44-56
35362116-6	2022	Similarly, cells were treated with WNT-agonist lithium chloride (LiCl), WNT-antagonist XAV-939 (XAV), or PKF-118-310 (PKF) with and without IL-1beta or TNF-alpha stimulation.	XAV939	87-90	Wnt family member 2	Rattus norvegicus	72-75
35472676-9	2022	Cyanidin and XAV-939 reversed the promoting effect of 30 atm pressure on Wnt/beta-catenin signaling pathway and the inhibiting effect on cell viability, proteoglycan synthesis and the level of cell matrix.	XAV939	13-20	Wnt family member 3A	Homo sapiens	73-76
35472676-9	2022	Cyanidin and XAV-939 reversed the promoting effect of 30 atm pressure on Wnt/beta-catenin signaling pathway and the inhibiting effect on cell viability, proteoglycan synthesis and the level of cell matrix.	XAV939	13-20	catenin beta 1	Homo sapiens	77-89
35587604-8	2022	Treatment with XAV-939, a beta-catenin inhibitor, significantly suppressed the cell proliferation and tumor growth induced by SIRT1 overexpression.	XAV939	15-22	catenin beta 1	Homo sapiens	26-38
35587604-8	2022	Treatment with XAV-939, a beta-catenin inhibitor, significantly suppressed the cell proliferation and tumor growth induced by SIRT1 overexpression.	XAV939	15-22	sirtuin 1	Homo sapiens	126-131
35347430-11	2022	After addition of XAV-939, reduction of beta-catenin and the downstream (Osterix and Runx2) were manifested.	XAV939	18-25	catenin beta 1	Rattus norvegicus	40-52
35347430-11	2022	After addition of XAV-939, reduction of beta-catenin and the downstream (Osterix and Runx2) were manifested.	XAV939	18-25	Sp7 transcription factor	Rattus norvegicus	73-80
35347430-11	2022	After addition of XAV-939, reduction of beta-catenin and the downstream (Osterix and Runx2) were manifested.	XAV939	18-25	RUNX family transcription factor 2	Rattus norvegicus	85-90
35230733-5	2022	However, these effects of ICS II were blunted by XAV-939, an inhibitor of Wnt/beta-catenin signaling pathway.	XAV939	49-56	wingless-type MMTV integration site family, member 3A	Mus musculus	74-77
35230733-5	2022	However, these effects of ICS II were blunted by XAV-939, an inhibitor of Wnt/beta-catenin signaling pathway.	XAV939	49-56	catenin (cadherin associated protein), beta 1	Mus musculus	78-90
35471485-5	2022	In addition, the enhanced protein expression of WNT2b and beta-catenin confirmed the activation of the WNT/beta-catenin signaling pathway and the WNT/beta-catenin inhibitor (XAV939) reversed the promoting effect of ADMSC-Exos on wound healing and the beta-catenin expression.	XAV939	174-180	Wnt family member 2B	Homo sapiens	48-53
35471485-5	2022	In addition, the enhanced protein expression of WNT2b and beta-catenin confirmed the activation of the WNT/beta-catenin signaling pathway and the WNT/beta-catenin inhibitor (XAV939) reversed the promoting effect of ADMSC-Exos on wound healing and the beta-catenin expression.	XAV939	174-180	catenin beta 1	Homo sapiens	58-70
35471485-5	2022	In addition, the enhanced protein expression of WNT2b and beta-catenin confirmed the activation of the WNT/beta-catenin signaling pathway and the WNT/beta-catenin inhibitor (XAV939) reversed the promoting effect of ADMSC-Exos on wound healing and the beta-catenin expression.	XAV939	174-180	catenin beta 1	Homo sapiens	150-162
35471485-5	2022	In addition, the enhanced protein expression of WNT2b and beta-catenin confirmed the activation of the WNT/beta-catenin signaling pathway and the WNT/beta-catenin inhibitor (XAV939) reversed the promoting effect of ADMSC-Exos on wound healing and the beta-catenin expression.	XAV939	174-180	catenin beta 1	Homo sapiens	251-263
35529473-3	2022	The involvement of the Wnt/beta-catenin signaling was examined using Wnt/beta-catenin inhibitor (2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano(4,3-d)pyrimidin-4-ol (XAV-939)) and activator lithium chloride (LiCl).	XAV939	175-182	catenin beta 1	Homo sapiens	73-85
35367831-6	2022	Moreover, the beta-catenin inhibitor XAV939 or XAV939 combined with Glis2 overexpression markedly inhibited the apoptosis and EMT of HG-treated HK-2 cells.	XAV939	37-43	catenin beta 1	Homo sapiens	14-26
35297475-11	2022	CS treatment resulted in beta-catenin production and XAV939, a beta-catenin inhibitor, and inhibited the cell proliferation by CS treatment.	XAV939	53-59	citrate synthase	Homo sapiens	0-2
34908071-8	2022	Notably, all these effects of gamma-T3 on the MC3T3-E1 cells were completely blocked by the Wnt/beta-catenin signaling pathway inhibitor XAV-939.	XAV939	137-144	catenin (cadherin associated protein), beta 1	Mus musculus	96-108
35269974-6	2022	Treatment with XAV939, a selective TNKS1/2 inhibitor, suppressed neurite outgrowth and synapse formation.	XAV939	15-21	tankyrase	Homo sapiens	35-42
35088876-5	2022	In a separate experiment, the effect of DMY on OGD/R-induced HT22 cell injury was also observed in the presence of the Wnt/beta-catenin inhibitor, XAV939.	XAV939	147-153	catenin (cadherin associated protein), beta 1	Mus musculus	123-135
35077846-6	2022	However, XAV-939, an inhibitor of the Wnt/beta-catenin signaling pathway, inhibited these positive effects of JuA.	XAV939	9-16	Wnt family member 3A	Homo sapiens	38-41
35077846-6	2022	However, XAV-939, an inhibitor of the Wnt/beta-catenin signaling pathway, inhibited these positive effects of JuA.	XAV939	9-16	catenin beta 1	Homo sapiens	42-54
35237161-11	2022	The Wnt/beta-catenin inhibitor XAV-939 aggravated Dox-caused decline of beta-catenin and cardiomyocyte apoptosis and mitochondrial damage.	XAV939	31-38	catenin beta 1	Homo sapiens	8-20
35237161-11	2022	The Wnt/beta-catenin inhibitor XAV-939 aggravated Dox-caused decline of beta-catenin and cardiomyocyte apoptosis and mitochondrial damage.	XAV939	31-38	catenin beta 1	Homo sapiens	72-84
34889823-8	2022	Moreover, in vivo and in vitro, SKL2001 (a specific agonist of beta-catenin) or XAV939 (a specific inhibitor of beta-catenin) was applied to determine the role of beta-catenin in the impacts provided by dexmedetomidine.	XAV939	80-86	catenin (cadherin associated protein), beta 1	Mus musculus	112-124
35297475-11	2022	CS treatment resulted in beta-catenin production and XAV939, a beta-catenin inhibitor, and inhibited the cell proliferation by CS treatment.	XAV939	53-59	catenin beta 1	Homo sapiens	63-75
35355710-9	2022	Moreover, the PI3K/AKT and Wnt/beta-catenin signaling inhibitors, LY294002 and XAV-939, ameliorated BLM-meditated PF in vivo and relieved EMT in vivo and in vitro.	XAV939	79-86	thymoma viral proto-oncogene 1	Mus musculus	19-22
35355710-9	2022	Moreover, the PI3K/AKT and Wnt/beta-catenin signaling inhibitors, LY294002 and XAV-939, ameliorated BLM-meditated PF in vivo and relieved EMT in vivo and in vitro.	XAV939	79-86	catenin (cadherin associated protein), beta 1	Mus musculus	31-43
34017191-8	2021	Furthermore, AQP1 overexpression promoted the activation of Wnt/beta-catenin pathway, and XAV939, an inhibitor of Wnt/beta-catenin, canceled the above effects of AQP1 overexpression on MH7A cells.	XAV939	90-96	catenin beta 1	Homo sapiens	118-130
33894313-7	2021	Therefore, the beta-catenin-specific inhibitors XAV939 and PRI-724 rescued EMT in MUC15-deficientcell lines.	XAV939	48-54	catenin beta 1	Homo sapiens	15-27
33894313-7	2021	Therefore, the beta-catenin-specific inhibitors XAV939 and PRI-724 rescued EMT in MUC15-deficientcell lines.	XAV939	48-54	mucin 15, cell surface associated	Homo sapiens	82-87
33735820-9	2021	Inhibiting beta-catenin with XAV-939 effectively abrogated beta-catenin expression caused by lenvatinib treatment.	XAV939	29-36	catenin beta 1	Homo sapiens	11-23
33735820-9	2021	Inhibiting beta-catenin with XAV-939 effectively abrogated beta-catenin expression caused by lenvatinib treatment.	XAV939	29-36	catenin beta 1	Homo sapiens	59-71
34030936-5	2021	Inhibition of beta-catenin with XAV939 (a beta-catenin specific inhibitor) was further used for testing its effect on macrophage activation mediated by Dkk2 knockdown.	XAV939	32-38	catenin (cadherin associated protein), beta 1	Mus musculus	14-26
34030936-10	2021	Mechanistically, we observed that Dkk2 knockdown activated Wnt/beta-catenin signaling by promoting beta-catenin to translocate into the nuclei of macrophages, and XAV939 reversed the ameliorated effect of Dkk2 silencing macrophage activation.	XAV939	163-169	dickkopf WNT signaling pathway inhibitor 2	Mus musculus	205-209
34016181-11	2021	XAV-939, an inhibitor of beta-catenin, significantly promoted chondrogenesis, and SrR did not suppress this effect, while LiCl, an agonist of beta-catenin, strongly suppressed chondrogenesis, and SrR reversed this inhibitory effect.	XAV939	0-7	catenin beta 1	Rattus norvegicus	25-37
34006890-11	2021	Inhibition of Wnt signaling pathway activity, using XAV-939, reversed the effects of PHLDA3 overexpression in lung cancer cells; moreover, PHLDA3 could bind to GSK3beta.	XAV939	52-59	pleckstrin homology like domain family A member 3	Homo sapiens	85-91
34017191-8	2021	Furthermore, AQP1 overexpression promoted the activation of Wnt/beta-catenin pathway, and XAV939, an inhibitor of Wnt/beta-catenin, canceled the above effects of AQP1 overexpression on MH7A cells.	XAV939	90-96	aquaporin 1 (Colton blood group)	Homo sapiens	162-166
33743349-6	2021	The other tankyrase inhibitor, XAV939, also promoted retinal differentiation.	XAV939	31-37	tankyrase	Homo sapiens	10-19
33959891-10	2021	XAV-939, a Wnt/beta-catenin inhibitor, partially reversed the effects of POSTN on GC-1 spg cell proliferation.	XAV939	0-7	catenin (cadherin associated protein), beta 1	Mus musculus	15-27
33959891-10	2021	XAV-939, a Wnt/beta-catenin inhibitor, partially reversed the effects of POSTN on GC-1 spg cell proliferation.	XAV939	0-7	periostin, osteoblast specific factor	Mus musculus	73-78
33517171-7	2021	In addition, after adding the inhibitor XAV-939, Western blot was used to assess the correlation with the Wnt/beta-catenin signaling pathway.	XAV939	40-47	catenin beta 1	Homo sapiens	110-122
33959159-7	2021	Additionally, rats had obvious mechanical induced pain after CCD surgery and the pain was significantly alleviated after the application of the Wnt/beta-catenin pathway inhibitor XAV939.	XAV939	179-185	catenin beta 1	Rattus norvegicus	148-160
33517171-11	2021	Remarkably, after blocking the Wnt/beta-catenin signaling pathway with XAV-939, the effect of MK-4 was apparently reversed.	XAV939	71-78	catenin beta 1	Homo sapiens	35-47
33249091-6	2021	However, administration of the Wnt/beta-catenin inhibitor, XAV-939, blocked the reparative effects of Nhe1-deficient astrocytes.	XAV939	59-66	wingless-type MMTV integration site family, member 7A	Mus musculus	31-34
33398673-9	2021	Additional gene expression studies indicated that co-targeting the EGFR and Wnt/beta-catenin pathways with lapatinib and XAV939 (a tankyrase inhibitor) promoted mesenchymal to epithelial transition (MET).	XAV939	121-127	epidermal growth factor receptor	Homo sapiens	67-71
33398673-9	2021	Additional gene expression studies indicated that co-targeting the EGFR and Wnt/beta-catenin pathways with lapatinib and XAV939 (a tankyrase inhibitor) promoted mesenchymal to epithelial transition (MET).	XAV939	121-127	catenin beta 1	Homo sapiens	80-92
33398673-9	2021	Additional gene expression studies indicated that co-targeting the EGFR and Wnt/beta-catenin pathways with lapatinib and XAV939 (a tankyrase inhibitor) promoted mesenchymal to epithelial transition (MET).	XAV939	121-127	SAFB like transcription modulator	Homo sapiens	199-202
33717238-6	2021	Furthermore, stimulation of the Wnt/beta-catenin axis triggered by ethylparaben was impaired by XAV-939.	XAV939	96-99	catenin beta 1	Rattus norvegicus	36-48
33249091-6	2021	However, administration of the Wnt/beta-catenin inhibitor, XAV-939, blocked the reparative effects of Nhe1-deficient astrocytes.	XAV939	59-66	catenin (cadherin associated protein), beta 1	Mus musculus	35-47
33249091-6	2021	However, administration of the Wnt/beta-catenin inhibitor, XAV-939, blocked the reparative effects of Nhe1-deficient astrocytes.	XAV939	59-66	solute carrier family 9 (sodium/hydrogen exchanger), member 1	Mus musculus	102-106
33859987-8	2021	Inhibition of beta-catenin by a specific inhibitor XAV939, reversed the facilitating effects of N-cadherin downregulation on odontogenic differentiation of DPSCs.	XAV939	51-57	catenin (cadherin associated protein), beta 1	Mus musculus	14-26
33859987-8	2021	Inhibition of beta-catenin by a specific inhibitor XAV939, reversed the facilitating effects of N-cadherin downregulation on odontogenic differentiation of DPSCs.	XAV939	51-57	cadherin 2	Mus musculus	96-106
33565239-11	2021	The WNT signalling inhibitor, XAV-939, effectively disrupted the migration promotion effect induced by EXT1.	XAV939	30-37	exostosin glycosyltransferase 1	Homo sapiens	103-107
33790893-6	2021	Moreover, the administration of Wnt/beta-catenin signaling inhibitors, including XAV-939 and Wnt-C59, distinctly inhibits the upregulation of PD-L1 expression in the co-cultured BMFs.	XAV939	81-88	catenin (cadherin associated protein), beta 1	Mus musculus	36-48
33790893-6	2021	Moreover, the administration of Wnt/beta-catenin signaling inhibitors, including XAV-939 and Wnt-C59, distinctly inhibits the upregulation of PD-L1 expression in the co-cultured BMFs.	XAV939	81-88	CD274 antigen	Mus musculus	142-147
33790893-7	2021	The further combination administration of XAV-939 significantly potentiates the therapeutic outcome of PD-L1 blockade therapy in BMF-mixed tumors.	XAV939	42-49	CD274 antigen	Mus musculus	103-108
33854620-15	2021	Notably, treatment with the Wnt/beta-catenin inhibitor XAV939 dramatically attenuated the effects of TTC36 in GC cells.	XAV939	55-61	catenin beta 1	Homo sapiens	32-44
33417163-9	2021	Further study suggests that block Wnt/beta-catenin pathway using XAV939 alone or block TGF-beta/Smad pathway using LY2109761 could partially block pLECs fibrosis, but blocking Wnt/beta-catenin and TGF-beta/Smad pathway using combined XAV939 and LY2109761 could completely block pLECs fibrosis.	XAV939	65-71	wingless-type MMTV integration site family, member 10A	Mus musculus	34-37
33264103-7	2020	Furthermore, XAV939 is a selective beta-catenin-mediated transcription inhibitor that inhibited TRIM27- and SIX3-mediated NSCLC cell proliferation, migration, and invasion.	XAV939	13-19	catenin beta 1	Homo sapiens	35-47
32588268-9	2021	The effects of the high-intensity LED irradiation on BMSC osteogenic differentiation and mineralization were suppressed by treatment with the Wnt/beta-catenin inhibitor XAV939.	XAV939	169-175	catenin beta 1	Homo sapiens	146-158
33241896-7	2021	Additionally, XAV-939, a tankyrase inhibitor, increased iAT1 cells in passaged FD-AOs, suggesting that these cells were differentiated from hiPSC-derived AT2 (iAT2) cells through the inhibition of canonical Wnt signaling.	XAV939	14-21	tankyrase	Homo sapiens	25-34
33504419-13	2021	An activation of Wnt signaling induced by Wnt3a-conditioned medium (Wnt3a-CM) increased the expression of NOX4, whereas the Wnt signal inhibitor XAV939 inhibited the expression of NOX4.	XAV939	145-151	NADPH oxidase 4	Homo sapiens	180-184
33407494-3	2021	METHODS: PlGF was knocked down in H358 and H1975 cells by lentiviruses, which were then cultured under hypoxia (90% N2, 5%CO2 and 5%O2) for 24 h. PlGF was overexpressed in PC9 cells treated with XAV939, inhibitor of Wnt/beta-catenin signaling pathway.	XAV939	195-201	placental growth factor	Homo sapiens	9-13
33407494-8	2021	Consistently, XAV939, inhibitor of Wnt/beta-catenin pathway, also inhibited PlGF-induced cell proliferation, glycolysis, and beta-catenin expression in PC9 cells.	XAV939	14-20	catenin beta 1	Homo sapiens	39-51
33407494-8	2021	Consistently, XAV939, inhibitor of Wnt/beta-catenin pathway, also inhibited PlGF-induced cell proliferation, glycolysis, and beta-catenin expression in PC9 cells.	XAV939	14-20	placental growth factor	Homo sapiens	76-80
33407494-8	2021	Consistently, XAV939, inhibitor of Wnt/beta-catenin pathway, also inhibited PlGF-induced cell proliferation, glycolysis, and beta-catenin expression in PC9 cells.	XAV939	14-20	catenin beta 1	Homo sapiens	125-137
33518533-10	2021	Treatment with XAV939, an inhibitor of the Wnt/beta-catenin pathway, attenuated the MA-induced increase in beta-catenin nuclear translocation.	XAV939	15-21	catenin beta 1	Homo sapiens	47-59
33518533-10	2021	Treatment with XAV939, an inhibitor of the Wnt/beta-catenin pathway, attenuated the MA-induced increase in beta-catenin nuclear translocation.	XAV939	15-21	catenin beta 1	Homo sapiens	107-119
33608625-0	2021	Author Correction: Tankyrase inhibitor XAV-939 enhances osteoblastogenesis and mineralization of human skeletal (mesenchymal) stem cells.	XAV939	39-46	tankyrase	Homo sapiens	19-28
33300054-11	2021	The results from rescue experiments further demonstrated that the effect of miR-576-5p overexpression on cell metastasis and EMT was reversed by Wnt5a overexpression or treatment with XAV-939, which is an inhibitor of the Wnt/beta-catenin signaling pathway.	XAV939	184-191	catenin beta 1	Homo sapiens	226-238
33504419-13	2021	An activation of Wnt signaling induced by Wnt3a-conditioned medium (Wnt3a-CM) increased the expression of NOX4, whereas the Wnt signal inhibitor XAV939 inhibited the expression of NOX4.	XAV939	145-151	Wnt family member 3A	Homo sapiens	17-20
33144683-6	2021	PHB1 deficiency in CRC cells decreased AXIN1 expression and increased beta-catenin activation that was abolished by XAV939, a pharmacological AXIN stabilizer.	XAV939	116-122	prohibitin 1	Homo sapiens	0-4
33144683-6	2021	PHB1 deficiency in CRC cells decreased AXIN1 expression and increased beta-catenin activation that was abolished by XAV939, a pharmacological AXIN stabilizer.	XAV939	116-122	axin 1	Homo sapiens	39-44
33144683-6	2021	PHB1 deficiency in CRC cells decreased AXIN1 expression and increased beta-catenin activation that was abolished by XAV939, a pharmacological AXIN stabilizer.	XAV939	116-122	catenin beta 1	Homo sapiens	70-82
33144683-6	2021	PHB1 deficiency in CRC cells decreased AXIN1 expression and increased beta-catenin activation that was abolished by XAV939, a pharmacological AXIN stabilizer.	XAV939	116-122	axin 1	Homo sapiens	39-43
33264103-7	2020	Furthermore, XAV939 is a selective beta-catenin-mediated transcription inhibitor that inhibited TRIM27- and SIX3-mediated NSCLC cell proliferation, migration, and invasion.	XAV939	13-19	tripartite motif containing 27	Homo sapiens	96-102
33264103-7	2020	Furthermore, XAV939 is a selective beta-catenin-mediated transcription inhibitor that inhibited TRIM27- and SIX3-mediated NSCLC cell proliferation, migration, and invasion.	XAV939	13-19	SIX homeobox 3	Homo sapiens	108-112
33173996-7	2020	Furthermore, the beta-catenin signaling inhibitor XAV-939 weakened the inhibitory effect of 1,25(OH)2D3 on osteogenic differentiation.	XAV939	50-57	catenin beta 1	Homo sapiens	17-29
32768578-11	2020	Besides, XAV939 (an inhibitor of the Wnt/beta-catenin pathway) proved the connection of JLX001 and Wnt/beta-catenin pathway.	XAV939	9-15	catenin beta 1	Rattus norvegicus	41-53
33132177-6	2020	METHODS: Rats were divided into sham group, SCI group, SCI + metformin group, metformin + XAV939 group (XAV939 is an effective inhibitor of the Wnt/beta-catenin signaling pathway), and methylprednisolone group.	XAV939	104-110	catenin beta 1	Rattus norvegicus	148-160
33002563-7	2020	Here, we report that XAV939 treatment, a tankyrase inhibitor, improves insulin-stimulated glucose uptake in insulin-sensitive as well as in insulin-resistant neuronal cells via AMP-activated protein kinase (AMPK) - AKT Substrate of 160 kDa (AS160) mediated pathway without affecting the phosphorylation/activation of AKT.	XAV939	21-27	TBC1 domain family, member 4	Mus musculus	215-239
33002563-7	2020	Here, we report that XAV939 treatment, a tankyrase inhibitor, improves insulin-stimulated glucose uptake in insulin-sensitive as well as in insulin-resistant neuronal cells via AMP-activated protein kinase (AMPK) - AKT Substrate of 160 kDa (AS160) mediated pathway without affecting the phosphorylation/activation of AKT.	XAV939	21-27	thymoma viral proto-oncogene 1	Mus musculus	215-218
32942006-8	2020	Furthermore, we used XAV939, an beta-catenin inhibitor, to verify the mechanism of DUD.	XAV939	21-27	catenin beta 1	Homo sapiens	32-44
32916221-8	2020	Notably, the protection of XQ-1H was abolished by Wnt/GSK3beta/beta-catenin inhibitor XAV939 or beta-catenin siRNA, indicating XQ-1H exerted protection in a Wnt/GSK3beta/beta-catenin dependent profile.	XAV939	86-92	glycogen synthase kinase 3 alpha	Mus musculus	54-62
32916221-8	2020	Notably, the protection of XQ-1H was abolished by Wnt/GSK3beta/beta-catenin inhibitor XAV939 or beta-catenin siRNA, indicating XQ-1H exerted protection in a Wnt/GSK3beta/beta-catenin dependent profile.	XAV939	86-92	catenin (cadherin associated protein), beta 1	Mus musculus	63-75
32916221-8	2020	Notably, the protection of XQ-1H was abolished by Wnt/GSK3beta/beta-catenin inhibitor XAV939 or beta-catenin siRNA, indicating XQ-1H exerted protection in a Wnt/GSK3beta/beta-catenin dependent profile.	XAV939	86-92	glycogen synthase kinase 3 alpha	Mus musculus	161-169
32768578-11	2020	Besides, XAV939 (an inhibitor of the Wnt/beta-catenin pathway) proved the connection of JLX001 and Wnt/beta-catenin pathway.	XAV939	9-15	catenin beta 1	Rattus norvegicus	103-115
33094479-5	2021	Treatment with or without XAV939, to inhibit YAP activation, was performed in these models.	XAV939	26-32	yes-associated protein 1	Mus musculus	45-48
33094479-12	2021	Application of XAV939 inhibited YAP protein dephosphorylation and reduced JNK pro-inflammatory pathway factor expression in vivo and in vitro.	XAV939	15-21	yes-associated protein 1	Mus musculus	32-35
33094479-12	2021	Application of XAV939 inhibited YAP protein dephosphorylation and reduced JNK pro-inflammatory pathway factor expression in vivo and in vitro.	XAV939	15-21	mitogen-activated protein kinase 8	Mus musculus	74-77
32840291-8	2020	The beta-catenin inhibitor XAV-939 suppressed quercetin-induced expressions of beta-catenin, c-Myc, and cyclins A2 and E1.	XAV939	27-34	catenin beta 1	Homo sapiens	4-16
32840291-8	2020	The beta-catenin inhibitor XAV-939 suppressed quercetin-induced expressions of beta-catenin, c-Myc, and cyclins A2 and E1.	XAV939	27-34	catenin beta 1	Homo sapiens	79-91
32840291-8	2020	The beta-catenin inhibitor XAV-939 suppressed quercetin-induced expressions of beta-catenin, c-Myc, and cyclins A2 and E1.	XAV939	27-34	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	93-98
32840291-8	2020	The beta-catenin inhibitor XAV-939 suppressed quercetin-induced expressions of beta-catenin, c-Myc, and cyclins A2 and E1.	XAV939	27-34	cyclin A2	Homo sapiens	104-121
32819607-5	2020	XAV939, as a tankyrase 1 inhibitor, could block the signaling pathway of Wnt/beta-catenin, which significantly reversed the change introduced by UBE2M.	XAV939	0-6	tankyrase	Homo sapiens	13-24
32822724-7	2020	Moreover, XAV939, an inhibitor of beta-Catenin, reversed the HOXA13-mediated effects on invasion and proliferation of colon cancer cells.	XAV939	10-16	catenin beta 1	Homo sapiens	34-46
32822724-7	2020	Moreover, XAV939, an inhibitor of beta-Catenin, reversed the HOXA13-mediated effects on invasion and proliferation of colon cancer cells.	XAV939	10-16	homeobox A13	Homo sapiens	61-67
33028869-0	2020	Tankyrase inhibitor XAV-939 enhances osteoblastogenesis and mineralization of human skeletal (mesenchymal) stem cells.	XAV939	20-27	tankyrase	Homo sapiens	0-9
33028869-6	2020	A Tankyrase inhibitor, XAV-939, identified during a functional library screening of small molecules.	XAV939	23-30	tankyrase	Homo sapiens	2-11
33028869-9	2020	XAV-939, a Tankyrase inhibitor, enhanced osteoblast differentiation of hBMSCs as evidenced by increased ALP activity, in vitro mineralized matrix formation, and upregulation of osteoblast-related gene expression.	XAV939	0-7	tankyrase	Homo sapiens	11-20
33028869-9	2020	XAV-939, a Tankyrase inhibitor, enhanced osteoblast differentiation of hBMSCs as evidenced by increased ALP activity, in vitro mineralized matrix formation, and upregulation of osteoblast-related gene expression.	XAV939	0-7	alkaline phosphatase, placental	Homo sapiens	104-107
33036206-11	2020	The protective effects of lipid emulsion and survival-related expression of genes such as Akt, GSK-3beta, Wnt1 and beta-catenin were reversed by the intra-peritoneal administration of XAV939 through the inhibition of the Wnt/beta-catenin signaling pathway.	XAV939	184-190	AKT serine/threonine kinase 1	Rattus norvegicus	90-93
33036206-11	2020	The protective effects of lipid emulsion and survival-related expression of genes such as Akt, GSK-3beta, Wnt1 and beta-catenin were reversed by the intra-peritoneal administration of XAV939 through the inhibition of the Wnt/beta-catenin signaling pathway.	XAV939	184-190	glycogen synthase kinase 3 alpha	Rattus norvegicus	95-104
33036206-11	2020	The protective effects of lipid emulsion and survival-related expression of genes such as Akt, GSK-3beta, Wnt1 and beta-catenin were reversed by the intra-peritoneal administration of XAV939 through the inhibition of the Wnt/beta-catenin signaling pathway.	XAV939	184-190	Wnt family member 1	Rattus norvegicus	106-110
33036206-11	2020	The protective effects of lipid emulsion and survival-related expression of genes such as Akt, GSK-3beta, Wnt1 and beta-catenin were reversed by the intra-peritoneal administration of XAV939 through the inhibition of the Wnt/beta-catenin signaling pathway.	XAV939	184-190	catenin beta 1	Rattus norvegicus	115-127
33036206-11	2020	The protective effects of lipid emulsion and survival-related expression of genes such as Akt, GSK-3beta, Wnt1 and beta-catenin were reversed by the intra-peritoneal administration of XAV939 through the inhibition of the Wnt/beta-catenin signaling pathway.	XAV939	184-190	Wnt family member 1	Rattus norvegicus	106-109
33036206-11	2020	The protective effects of lipid emulsion and survival-related expression of genes such as Akt, GSK-3beta, Wnt1 and beta-catenin were reversed by the intra-peritoneal administration of XAV939 through the inhibition of the Wnt/beta-catenin signaling pathway.	XAV939	184-190	catenin beta 1	Rattus norvegicus	225-237
32830537-8	2020	Interestingly, (P)RR or Wnt4-specific siRNA treatment or the beta-catenin antagonist XAV939 inhibited the elevation of MCP-1 expression, whereas DRI did not.	XAV939	85-91	catenin beta 1	Rattus norvegicus	61-73
32830537-8	2020	Interestingly, (P)RR or Wnt4-specific siRNA treatment or the beta-catenin antagonist XAV939 inhibited the elevation of MCP-1 expression, whereas DRI did not.	XAV939	85-91	C-C motif chemokine ligand 2	Rattus norvegicus	119-124
32191839-8	2020	Besides, PYGB overexpression also activated Wnt pathway and Sh-PYGB showed the opposite results, which were abrogated by XAV-939 (a beta-catenin Inhibitor) or overexpression of beta-catenin, respectively.	XAV939	121-128	glycogen phosphorylase B	Homo sapiens	9-13
32191839-8	2020	Besides, PYGB overexpression also activated Wnt pathway and Sh-PYGB showed the opposite results, which were abrogated by XAV-939 (a beta-catenin Inhibitor) or overexpression of beta-catenin, respectively.	XAV939	121-128	glycogen phosphorylase B	Homo sapiens	63-67
32191839-8	2020	Besides, PYGB overexpression also activated Wnt pathway and Sh-PYGB showed the opposite results, which were abrogated by XAV-939 (a beta-catenin Inhibitor) or overexpression of beta-catenin, respectively.	XAV939	121-128	catenin beta 1	Homo sapiens	132-144
32717269-7	2020	Additionally, the tankyrase inhibitor, XAV939, was used to determine the role of the Wnt/beta-catenin pathway.	XAV939	39-45	tankyrase	Homo sapiens	18-27
32717269-10	2020	After blocking the Wnt/beta-catenin pathway with XAV939, the effects of kaempferol were apparently reversed.	XAV939	49-55	catenin beta 1	Homo sapiens	23-35
32945491-7	2020	Furthermore, XAV939-induced Wnt signaling suppression reversed the ASTN1-mediated inhibition of invasion and migration in cells.	XAV939	13-19	astrotactin 1	Homo sapiens	67-72
33163270-5	2020	Furthermore, activation of the Wnt/beta-catenin pathway by LiCl restored the effect of TDP-43 knockdown on EMT and HCC cells, whereas inhibition of the Wnt/beta-catenin pathway by XAV939 negated the effect of TDP-43 overexpression.	XAV939	180-186	catenin beta 1	Homo sapiens	156-168
32819607-5	2020	XAV939, as a tankyrase 1 inhibitor, could block the signaling pathway of Wnt/beta-catenin, which significantly reversed the change introduced by UBE2M.	XAV939	0-6	catenin beta 1	Homo sapiens	77-89
32819607-5	2020	XAV939, as a tankyrase 1 inhibitor, could block the signaling pathway of Wnt/beta-catenin, which significantly reversed the change introduced by UBE2M.	XAV939	0-6	ubiquitin conjugating enzyme E2 M	Homo sapiens	145-150
32582975-6	2020	Treatment with the beta-catenin inhibitor XAV939, Gli1 siRNA, or miR-202-3p mimic transfection, attenuated the IL-1beta-induced suppression of OPC proliferation and differentiation.	XAV939	42-48	catenin beta 1	Homo sapiens	19-31
32582975-6	2020	Treatment with the beta-catenin inhibitor XAV939, Gli1 siRNA, or miR-202-3p mimic transfection, attenuated the IL-1beta-induced suppression of OPC proliferation and differentiation.	XAV939	42-48	interleukin 1 alpha	Homo sapiens	111-119
32582975-7	2020	Treatment with XAV939 decreased the expression of Gli1.	XAV939	15-21	GLI family zinc finger 1	Homo sapiens	50-54
33099905-4	2020	LCSCs were transfected with empty lentivirus in the control group and transfected with AQP3 shRNA in the interference group, and the low expression of AQP3 was inhibited using the Wnt pathway inhibitor XAV939 in the interference+inhibitor group.	XAV939	202-208	aquaporin 3 (Gill blood group)	Homo sapiens	87-91
32801867-10	2020	Blocking of wnt/beta-catenin using XAV-939 reversed the promotion role of FGD3-AS1 on glioma cells" migration and invasion.	XAV939	35-42	catenin (cadherin associated protein), beta 1	Mus musculus	16-28
32801867-10	2020	Blocking of wnt/beta-catenin using XAV-939 reversed the promotion role of FGD3-AS1 on glioma cells" migration and invasion.	XAV939	35-42	FYVE, RhoGEF and PH domain containing 3	Mus musculus	74-78
32801867-10	2020	Blocking of wnt/beta-catenin using XAV-939 reversed the promotion role of FGD3-AS1 on glioma cells" migration and invasion.	XAV939	35-42	arylsulfatase B	Mus musculus	79-82
33099905-4	2020	LCSCs were transfected with empty lentivirus in the control group and transfected with AQP3 shRNA in the interference group, and the low expression of AQP3 was inhibited using the Wnt pathway inhibitor XAV939 in the interference+inhibitor group.	XAV939	202-208	aquaporin 3 (Gill blood group)	Homo sapiens	151-155
33099905-4	2020	LCSCs were transfected with empty lentivirus in the control group and transfected with AQP3 shRNA in the interference group, and the low expression of AQP3 was inhibited using the Wnt pathway inhibitor XAV939 in the interference+inhibitor group.	XAV939	202-208	Wnt family member 5A	Homo sapiens	180-183
32636646-13	2020	XAV939, an inhibitor of Wnt/beta-catenin signaling pathway, decreased GOLPH3 overexpression-induced proliferation and enhanced cisplatin-induced angiogenesis inhibition and apoptosis, which was supported by the changes of VEGF, Bax and Bcl-2.	XAV939	0-6	catenin beta 1	Homo sapiens	28-40
32636646-13	2020	XAV939, an inhibitor of Wnt/beta-catenin signaling pathway, decreased GOLPH3 overexpression-induced proliferation and enhanced cisplatin-induced angiogenesis inhibition and apoptosis, which was supported by the changes of VEGF, Bax and Bcl-2.	XAV939	0-6	golgi phosphoprotein 3	Homo sapiens	70-76
32636646-13	2020	XAV939, an inhibitor of Wnt/beta-catenin signaling pathway, decreased GOLPH3 overexpression-induced proliferation and enhanced cisplatin-induced angiogenesis inhibition and apoptosis, which was supported by the changes of VEGF, Bax and Bcl-2.	XAV939	0-6	vascular endothelial growth factor A	Homo sapiens	222-226
32636646-13	2020	XAV939, an inhibitor of Wnt/beta-catenin signaling pathway, decreased GOLPH3 overexpression-induced proliferation and enhanced cisplatin-induced angiogenesis inhibition and apoptosis, which was supported by the changes of VEGF, Bax and Bcl-2.	XAV939	0-6	BCL2 associated X, apoptosis regulator	Homo sapiens	228-231
32636646-13	2020	XAV939, an inhibitor of Wnt/beta-catenin signaling pathway, decreased GOLPH3 overexpression-induced proliferation and enhanced cisplatin-induced angiogenesis inhibition and apoptosis, which was supported by the changes of VEGF, Bax and Bcl-2.	XAV939	0-6	BCL2 apoptosis regulator	Homo sapiens	236-241
32179851-11	2020	Finally, treatment with the Wnt/beta-catenin inhibitor XAV939 enhanced the sensitivity of PC9/ER cells to erlotinib.	XAV939	55-61	catenin beta 1	Homo sapiens	32-44
32251100-6	2020	However, XAV939 inhibited Wnt/beta-catenin signaling pathway, which significantly inhibited the regulatory effect of netrin-1 on apoptosis, inflammation, Nissl bodies, damaged tissues, and neuroprotection.	XAV939	9-15	catenin beta 1	Homo sapiens	30-42
32251100-6	2020	However, XAV939 inhibited Wnt/beta-catenin signaling pathway, which significantly inhibited the regulatory effect of netrin-1 on apoptosis, inflammation, Nissl bodies, damaged tissues, and neuroprotection.	XAV939	9-15	netrin 1	Homo sapiens	117-125
32323740-6	2020	XAV939 (an inhibitor of the Wnt/beta-catenin pathway) was used to confirm the effects of the Wnt/beta-catenin signaling pathway on exercise-mediated neurogenesis and myelin repair.	XAV939	0-6	Wnt family member 3A	Rattus norvegicus	28-31
32323740-6	2020	XAV939 (an inhibitor of the Wnt/beta-catenin pathway) was used to confirm the effects of the Wnt/beta-catenin signaling pathway on exercise-mediated neurogenesis and myelin repair.	XAV939	0-6	catenin beta 1	Rattus norvegicus	32-44
32323740-6	2020	XAV939 (an inhibitor of the Wnt/beta-catenin pathway) was used to confirm the effects of the Wnt/beta-catenin signaling pathway on exercise-mediated neurogenesis and myelin repair.	XAV939	0-6	Wnt family member 3A	Rattus norvegicus	93-96
32323740-13	2020	In addition, XAV939 inhibited treadmill exercise-induced neurogenesis and myelin repair, which was consistent with the downregulation of Wnt3a, nucleus beta-catenin, BDNF and MBP expression, and the deterioration of neurological function.	XAV939	13-19	Wnt family member 3A	Rattus norvegicus	137-142
32323740-13	2020	In addition, XAV939 inhibited treadmill exercise-induced neurogenesis and myelin repair, which was consistent with the downregulation of Wnt3a, nucleus beta-catenin, BDNF and MBP expression, and the deterioration of neurological function.	XAV939	13-19	catenin beta 1	Rattus norvegicus	152-164
32323740-13	2020	In addition, XAV939 inhibited treadmill exercise-induced neurogenesis and myelin repair, which was consistent with the downregulation of Wnt3a, nucleus beta-catenin, BDNF and MBP expression, and the deterioration of neurological function.	XAV939	13-19	brain-derived neurotrophic factor	Rattus norvegicus	166-170
32323740-13	2020	In addition, XAV939 inhibited treadmill exercise-induced neurogenesis and myelin repair, which was consistent with the downregulation of Wnt3a, nucleus beta-catenin, BDNF and MBP expression, and the deterioration of neurological function.	XAV939	13-19	myelin basic protein	Rattus norvegicus	175-178
32195172-10	2020	The inhibitor of the Wnt signaling pathway, XAV-939, reversed the promoting effect of FAM83A on YAP, cyclin E, and CTGF.	XAV939	44-51	family with sequence similarity 83 member A	Homo sapiens	86-92
32195172-10	2020	The inhibitor of the Wnt signaling pathway, XAV-939, reversed the promoting effect of FAM83A on YAP, cyclin E, and CTGF.	XAV939	44-51	Yes1 associated transcriptional regulator	Homo sapiens	96-99
32195172-10	2020	The inhibitor of the Wnt signaling pathway, XAV-939, reversed the promoting effect of FAM83A on YAP, cyclin E, and CTGF.	XAV939	44-51	cellular communication network factor 2	Homo sapiens	115-119
31944393-14	2020	These effects were blocked by XAV-939 (a Wnt signaling antagonist), and then rescued by additional Wnt3a (a Wnt agonist).	XAV939	30-37	wingless-type MMTV integration site family, member 3A	Mus musculus	41-44
32521874-3	2020	LCSCs were transfected with empty lentivirus in control group and transfected with AQP3 shRNA in interference group, and the low expression of AQP3 was inhibited using the Wnt pathway inhibitor XAV939 in interference + inhibitor group.	XAV939	194-200	aquaporin 3 (Gill blood group)	Homo sapiens	143-147
32521874-3	2020	LCSCs were transfected with empty lentivirus in control group and transfected with AQP3 shRNA in interference group, and the low expression of AQP3 was inhibited using the Wnt pathway inhibitor XAV939 in interference + inhibitor group.	XAV939	194-200	Wnt family member 5A	Homo sapiens	172-175
31977705-8	2020	Xav939 inhibited the Wnt/beta-catenin signaling pathway in estrogen-mediated environment, but did not obviously inhibit the osteogenic differentiation of hPDLSCs.	XAV939	0-6	Wnt family member 3A	Homo sapiens	21-24
31977705-8	2020	Xav939 inhibited the Wnt/beta-catenin signaling pathway in estrogen-mediated environment, but did not obviously inhibit the osteogenic differentiation of hPDLSCs.	XAV939	0-6	catenin beta 1	Homo sapiens	25-37
32596150-12	2020	Additionally, the expression of beta-catenin is positively related to UCHL5 levels and the tumorigenic effects of UCHL5 overexpression were reversed by the Wnt/beta-catenin pathway inhibitor XAV939.	XAV939	191-197	catenin beta 1	Homo sapiens	32-44
32596150-12	2020	Additionally, the expression of beta-catenin is positively related to UCHL5 levels and the tumorigenic effects of UCHL5 overexpression were reversed by the Wnt/beta-catenin pathway inhibitor XAV939.	XAV939	191-197	ubiquitin C-terminal hydrolase L5	Homo sapiens	70-75
32596150-12	2020	Additionally, the expression of beta-catenin is positively related to UCHL5 levels and the tumorigenic effects of UCHL5 overexpression were reversed by the Wnt/beta-catenin pathway inhibitor XAV939.	XAV939	191-197	ubiquitin C-terminal hydrolase L5	Homo sapiens	114-119
32596150-12	2020	Additionally, the expression of beta-catenin is positively related to UCHL5 levels and the tumorigenic effects of UCHL5 overexpression were reversed by the Wnt/beta-catenin pathway inhibitor XAV939.	XAV939	191-197	catenin beta 1	Homo sapiens	160-172
32536813-10	2020	The effects of ARHGAP30 knockdown were potently attenuated by the beta-catenin inhibitor XAV939.	XAV939	89-95	Rho GTPase activating protein 30	Homo sapiens	15-23
32536813-10	2020	The effects of ARHGAP30 knockdown were potently attenuated by the beta-catenin inhibitor XAV939.	XAV939	89-95	catenin beta 1	Homo sapiens	66-78
32298013-8	2020	Exogenous addition of FNDC4 protein could not restore the blocking of differentiation due to inhibition of both Wnt/beta-catenin signal transduction and LRP6 activity via the beta-catenin inhibitor XAV-939.	XAV939	198-205	catenin (cadherin associated protein), beta 1	Mus musculus	175-187
32236572-9	2020	FGFR4 silencing partially reversed EMT progression and FGFR4 this effect was enhanced in the presence of XAV939 (a beta-catenin inhibitor).	XAV939	105-111	fibroblast growth factor receptor 4	Homo sapiens	0-5
32236572-9	2020	FGFR4 silencing partially reversed EMT progression and FGFR4 this effect was enhanced in the presence of XAV939 (a beta-catenin inhibitor).	XAV939	105-111	fibroblast growth factor receptor 4	Homo sapiens	55-60
32236572-9	2020	FGFR4 silencing partially reversed EMT progression and FGFR4 this effect was enhanced in the presence of XAV939 (a beta-catenin inhibitor).	XAV939	105-111	catenin beta 1	Homo sapiens	115-127
32323840-9	2020	Following inhibition of the Wnt/beta-catenin signaling pathway using XAV939, the effects of ES were weakened.	XAV939	69-75	catenin beta 1	Rattus norvegicus	32-44
32547070-13	2020	Besides, the FAM110B-induced depressions of p-GSK-3beta and active beta-catenin were reversed after being treated with Wnt/beta-catenin inhibitor, XAV-939.	XAV939	147-154	family with sequence similarity 110 member B	Homo sapiens	13-20
32547070-13	2020	Besides, the FAM110B-induced depressions of p-GSK-3beta and active beta-catenin were reversed after being treated with Wnt/beta-catenin inhibitor, XAV-939.	XAV939	147-154	catenin beta 1	Homo sapiens	67-79
32547070-13	2020	Besides, the FAM110B-induced depressions of p-GSK-3beta and active beta-catenin were reversed after being treated with Wnt/beta-catenin inhibitor, XAV-939.	XAV939	147-154	catenin beta 1	Homo sapiens	123-135
31786079-11	2020	In addition, TRIM11 overexpression had an opposite effect to TRIM11 knockdown, and a beta-catenin inhibitor, XAV939, potently attenuated the induction of TRIM11 on lymphoma cells.	XAV939	109-115	catenin beta 1	Homo sapiens	85-97
31732998-8	2020	And inhibition of Wnt/beta-catenin signalling using XAV-939 could eliminate this phenomenon.	XAV939	52-59	catenin alpha-1	Oryctolagus cuniculus	22-34
32103979-12	2020	Moreover, Wnt/beta-catenin pathway inhibitor XAV939 could inhibit the expressions of c-myc, cyclin D1 and beta-catenin, but activator LiCl could promote their expression.	XAV939	45-51	catenin beta 1	Homo sapiens	14-26
32103979-12	2020	Moreover, Wnt/beta-catenin pathway inhibitor XAV939 could inhibit the expressions of c-myc, cyclin D1 and beta-catenin, but activator LiCl could promote their expression.	XAV939	45-51	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	85-90
32103979-12	2020	Moreover, Wnt/beta-catenin pathway inhibitor XAV939 could inhibit the expressions of c-myc, cyclin D1 and beta-catenin, but activator LiCl could promote their expression.	XAV939	45-51	cyclin D1	Homo sapiens	92-101
32103979-12	2020	Moreover, Wnt/beta-catenin pathway inhibitor XAV939 could inhibit the expressions of c-myc, cyclin D1 and beta-catenin, but activator LiCl could promote their expression.	XAV939	45-51	catenin beta 1	Homo sapiens	106-118
31969494-8	2020	The protective effect of CHS was remarkably suppressed by siRNAs against TCF7L2 or XAV-939 (a Wnt/beta-catenin antagonist) in vitro and in beta-catenin-/- mice.	XAV939	83-90	catenin (cadherin associated protein), beta 1	Mus musculus	98-110
31704613-9	2020	Importantly, we were able to overcome the resistance to 5-FU seen in CRC cells carrying short APC by tankyrase inhibitor, XAV939, thereby inhibiting Wnt/beta-catenin signaling cascade.	XAV939	122-128	tankyrase	Homo sapiens	101-110
31704613-9	2020	Importantly, we were able to overcome the resistance to 5-FU seen in CRC cells carrying short APC by tankyrase inhibitor, XAV939, thereby inhibiting Wnt/beta-catenin signaling cascade.	XAV939	122-128	catenin beta 1	Homo sapiens	153-165
31412145-11	2019	In the high glucose-stimulated NRK-52E cells, sitagliptin and XAV939 inhibited the elevated expression of Wnt4, beta-catenin, dipeptidyl peptidase-4, alpha-smooth muscle actin, transforming growth factor-beta and fibronectin and restored E-cadherin activity.	XAV939	62-68	Wnt family member 4	Rattus norvegicus	106-110
30958531-6	2019	Furthermore, treatment of CAY10683, an HDAC2 inhibitor, and XAV939, a Wnt/beta-catenin pathway inhibitor, attenuated the effects of ARHGAP4 silencing on pancreatic cancer cells.	XAV939	60-66	catenin beta 1	Homo sapiens	74-86
30958531-6	2019	Furthermore, treatment of CAY10683, an HDAC2 inhibitor, and XAV939, a Wnt/beta-catenin pathway inhibitor, attenuated the effects of ARHGAP4 silencing on pancreatic cancer cells.	XAV939	60-66	Rho GTPase activating protein 4	Homo sapiens	132-139
31605677-8	2019	Furthermore, our data confirmed that the promoting effects of fusion of macrophages on breast cancer cell proliferation, migration and invasion could be blocked by treatment with XAV-939, a Wnt/beta-catenin signaling pathway inhibitor.	XAV939	179-186	catenin beta 1	Homo sapiens	194-206
31155960-5	2019	Next, we used XAV-939 to inhibit the Wnt/beta-catenin pathway and explore the relevant mechanism.	XAV939	14-21	catenin beta 1	Homo sapiens	41-53
31087357-4	2019	We also demonstrated that the inhibition of beta-catenin by means of two molecules, XAV939 and ICG-001, decreased the proliferation of the IGROV1 and SKOV3 ovarian cancer cell lines and that ICG-001 increased the percentage of IGROV1 cells undergoing apoptosis.	XAV939	84-90	catenin beta 1	Homo sapiens	44-56
31632077-9	2019	Moreover, LiCl (beta-catenin activator) enhanced the regulatory effects of SOX17 on the expression of E-cadherin, promigratory cadherin, vimentin, and proteins in the Wnt signaling pathway, while XAV93920 (beta-catenin inhibitor) exerted the opposite effect.	XAV939	196-204	catenin beta 1	Homo sapiens	16-28
31412145-11	2019	In the high glucose-stimulated NRK-52E cells, sitagliptin and XAV939 inhibited the elevated expression of Wnt4, beta-catenin, dipeptidyl peptidase-4, alpha-smooth muscle actin, transforming growth factor-beta and fibronectin and restored E-cadherin activity.	XAV939	62-68	catenin beta 1	Rattus norvegicus	112-124
31412145-11	2019	In the high glucose-stimulated NRK-52E cells, sitagliptin and XAV939 inhibited the elevated expression of Wnt4, beta-catenin, dipeptidyl peptidase-4, alpha-smooth muscle actin, transforming growth factor-beta and fibronectin and restored E-cadherin activity.	XAV939	62-68	dipeptidylpeptidase 4	Rattus norvegicus	126-148
31412145-11	2019	In the high glucose-stimulated NRK-52E cells, sitagliptin and XAV939 inhibited the elevated expression of Wnt4, beta-catenin, dipeptidyl peptidase-4, alpha-smooth muscle actin, transforming growth factor-beta and fibronectin and restored E-cadherin activity.	XAV939	62-68	actin gamma 2, smooth muscle	Rattus norvegicus	150-175
31412145-11	2019	In the high glucose-stimulated NRK-52E cells, sitagliptin and XAV939 inhibited the elevated expression of Wnt4, beta-catenin, dipeptidyl peptidase-4, alpha-smooth muscle actin, transforming growth factor-beta and fibronectin and restored E-cadherin activity.	XAV939	62-68	fibronectin 1	Rattus norvegicus	213-224
31412145-11	2019	In the high glucose-stimulated NRK-52E cells, sitagliptin and XAV939 inhibited the elevated expression of Wnt4, beta-catenin, dipeptidyl peptidase-4, alpha-smooth muscle actin, transforming growth factor-beta and fibronectin and restored E-cadherin activity.	XAV939	62-68	cadherin 1	Rattus norvegicus	238-248
31416135-6	2019	The paclitaxel-combined XAV939 treatment induced apoptosis by suppressing Bcl-2 and by increasing the cleavage of caspases-3 and PARP.	XAV939	24-30	BCL2 apoptosis regulator	Homo sapiens	74-79
31026457-9	2019	beta-Catenin antagonist (XAV939) was used to block LPS-mediated upregulation of iNOS, TNF-alpha, cyclin-D1, nitric oxide (NO) and the number of cells in the G2/M+S phase of cell cycle.	XAV939	25-31	catenin beta 1	Rattus norvegicus	0-12
31026457-9	2019	beta-Catenin antagonist (XAV939) was used to block LPS-mediated upregulation of iNOS, TNF-alpha, cyclin-D1, nitric oxide (NO) and the number of cells in the G2/M+S phase of cell cycle.	XAV939	25-31	nitric oxide synthase 2	Rattus norvegicus	80-84
31026457-9	2019	beta-Catenin antagonist (XAV939) was used to block LPS-mediated upregulation of iNOS, TNF-alpha, cyclin-D1, nitric oxide (NO) and the number of cells in the G2/M+S phase of cell cycle.	XAV939	25-31	tumor necrosis factor	Rattus norvegicus	86-95
31026457-9	2019	beta-Catenin antagonist (XAV939) was used to block LPS-mediated upregulation of iNOS, TNF-alpha, cyclin-D1, nitric oxide (NO) and the number of cells in the G2/M+S phase of cell cycle.	XAV939	25-31	cyclin D1	Rattus norvegicus	97-106
31416135-6	2019	The paclitaxel-combined XAV939 treatment induced apoptosis by suppressing Bcl-2 and by increasing the cleavage of caspases-3 and PARP.	XAV939	24-30	collagen type XI alpha 2 chain	Homo sapiens	129-133
31416135-8	2019	Furthermore, the paclitaxel-combined XAV939 treatment reduced the expression of beta-catenin, a key molecule in the Wnt pathway, which led to suppression of the expression of epithelial-mesenchymal transition (EMT) markers and angiogenic proteins both at mRNA and protein levels.	XAV939	37-43	catenin beta 1	Homo sapiens	80-92
31002351-5	2019	Additionally, TRIM52-induced cell proliferation and invasiveness, as well as the levels of cell cycle-associated proteins, were completely counteracted by the Wnt/beta-catenin inhibitor XAV939.	XAV939	186-192	tripartite motif containing 52	Homo sapiens	14-20
31006055-10	2019	The bLF-mediated DP cell proliferation could be significantly reversed by the Wnt pathway inhibitor XAV939.	XAV939	100-106	wingless-type MMTV integration site family, member 3A	Mus musculus	78-81
31124219-5	2019	Combining PI3K inhibitor LY294002 with XAV-939, an inhibitor against beta-catenin nuclear accumulation, produced an additive anti-proliferation effect against breast cancer cells.	XAV939	39-46	catenin beta 1	Homo sapiens	69-81
31316620-7	2019	C6 cells transfected with miR-24 mimics or negative control miRNAs were treated with the beta-catenin inhibitor, XAV-939.	XAV939	113-120	catenin beta 1	Homo sapiens	89-101
31316620-13	2019	XAV-939 attenuated the miR-24-induced decrease of the protein expression of LC3B and Beclin1, and decreased the stimulatory effects of miR-24 mimics on cell viability.	XAV939	0-3	microtubule associated protein 1 light chain 3 beta	Homo sapiens	76-80
31316620-13	2019	XAV-939 attenuated the miR-24-induced decrease of the protein expression of LC3B and Beclin1, and decreased the stimulatory effects of miR-24 mimics on cell viability.	XAV939	0-3	beclin 1	Homo sapiens	85-92
30652305-8	2019	Furthermore, treatment with XAV939, an inhibitor of Wnt/beta-catenin, reduced the podocan-mediated promotion of C2C12 differentiation.	XAV939	28-34	catenin (cadherin associated protein), beta 1	Mus musculus	56-68
30652305-8	2019	Furthermore, treatment with XAV939, an inhibitor of Wnt/beta-catenin, reduced the podocan-mediated promotion of C2C12 differentiation.	XAV939	28-34	podocan	Mus musculus	82-89
31270046-6	2019	XAV-939, a GSK-3beta/beta-catenin inhibitor, was used for assessing the impact of lincRNAUFC1 overexpression on the invasion and migration of the HCC cells through Transwell and wound-healing assays.	XAV939	0-7	glycogen synthase kinase 3 beta	Homo sapiens	11-20
31270046-6	2019	XAV-939, a GSK-3beta/beta-catenin inhibitor, was used for assessing the impact of lincRNAUFC1 overexpression on the invasion and migration of the HCC cells through Transwell and wound-healing assays.	XAV939	0-7	catenin beta 1	Homo sapiens	21-33
31285694-8	2019	XAV-939, an inhibitor of beta-catenin accumulation could reverse DKK1 silencing-induced MMP7 expression in breast cancer cells.	XAV939	0-7	catenin beta 1	Homo sapiens	25-37
31285694-8	2019	XAV-939, an inhibitor of beta-catenin accumulation could reverse DKK1 silencing-induced MMP7 expression in breast cancer cells.	XAV939	0-7	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	65-69
31285694-8	2019	XAV-939, an inhibitor of beta-catenin accumulation could reverse DKK1 silencing-induced MMP7 expression in breast cancer cells.	XAV939	0-7	matrix metallopeptidase 7	Homo sapiens	88-92
30466341-0	2019	XAV939, a Wnt/beta-catenin pathway modulator, has inhibitory effects on LPS-induced inflammatory response.	XAV939	0-6	catenin beta 1	Homo sapiens	14-26
30466341-1	2019	Aim: In this study, we report the anti-inflammatory activity of XAV939, a modulator of the Wnt/beta-catenin pathway.	XAV939	64-70	catenin beta 1	Homo sapiens	95-107
30466341-4	2019	Results: LPS-induced expressions of pro-inflammatory genes IL-6, IL-8, TNF-alpha, IL-1beta, MCP-1, MMP-9, iNOS and COX-2 were significantly and dose-dependently suppressed by XAV939.	XAV939	175-181	interleukin 6	Homo sapiens	59-63
30466341-4	2019	Results: LPS-induced expressions of pro-inflammatory genes IL-6, IL-8, TNF-alpha, IL-1beta, MCP-1, MMP-9, iNOS and COX-2 were significantly and dose-dependently suppressed by XAV939.	XAV939	175-181	C-X-C motif chemokine ligand 8	Homo sapiens	65-69
30466341-4	2019	Results: LPS-induced expressions of pro-inflammatory genes IL-6, IL-8, TNF-alpha, IL-1beta, MCP-1, MMP-9, iNOS and COX-2 were significantly and dose-dependently suppressed by XAV939.	XAV939	175-181	tumor necrosis factor	Homo sapiens	71-80
30466341-4	2019	Results: LPS-induced expressions of pro-inflammatory genes IL-6, IL-8, TNF-alpha, IL-1beta, MCP-1, MMP-9, iNOS and COX-2 were significantly and dose-dependently suppressed by XAV939.	XAV939	175-181	interleukin 1 alpha	Homo sapiens	82-90
30466341-4	2019	Results: LPS-induced expressions of pro-inflammatory genes IL-6, IL-8, TNF-alpha, IL-1beta, MCP-1, MMP-9, iNOS and COX-2 were significantly and dose-dependently suppressed by XAV939.	XAV939	175-181	C-C motif chemokine ligand 2	Homo sapiens	92-97
30466341-4	2019	Results: LPS-induced expressions of pro-inflammatory genes IL-6, IL-8, TNF-alpha, IL-1beta, MCP-1, MMP-9, iNOS and COX-2 were significantly and dose-dependently suppressed by XAV939.	XAV939	175-181	matrix metallopeptidase 9	Homo sapiens	99-104
30466341-4	2019	Results: LPS-induced expressions of pro-inflammatory genes IL-6, IL-8, TNF-alpha, IL-1beta, MCP-1, MMP-9, iNOS and COX-2 were significantly and dose-dependently suppressed by XAV939.	XAV939	175-181	inositol-3-phosphate synthase 1	Homo sapiens	106-110
30466341-4	2019	Results: LPS-induced expressions of pro-inflammatory genes IL-6, IL-8, TNF-alpha, IL-1beta, MCP-1, MMP-9, iNOS and COX-2 were significantly and dose-dependently suppressed by XAV939.	XAV939	175-181	mitochondrially encoded cytochrome c oxidase II	Homo sapiens	115-120
30466341-5	2019	LPS-induced NF-kappaB signaling, such as IkappaB phosphorylation and degradation as well as nuclear translocation of NF-kappaB, was also suppressed by XAV939.	XAV939	151-157	nuclear factor kappa B subunit 1	Homo sapiens	12-21
30466341-5	2019	LPS-induced NF-kappaB signaling, such as IkappaB phosphorylation and degradation as well as nuclear translocation of NF-kappaB, was also suppressed by XAV939.	XAV939	151-157	nuclear factor kappa B subunit 1	Homo sapiens	117-126
30466341-6	2019	Target DNA binding of NF-kappaB was significantly and dose-dependently suppressed by XAV939 during LPS-induced inflammatory response.	XAV939	85-91	nuclear factor kappa B subunit 1	Homo sapiens	22-31
30466341-7	2019	The suppressive effects of XAV939 on NF-kappaB signaling, target DNA binding of NF-kappaB and pro-inflammatory gene expression were all rescued by over expression of beta-catenin, which shows that the anti-inflammatory effect of XAV939 is mediated by the modulation of beta-catenin, a central component of the WNT/beta-catenin pathway.	XAV939	27-33	nuclear factor kappa B subunit 1	Homo sapiens	37-46
30466341-7	2019	The suppressive effects of XAV939 on NF-kappaB signaling, target DNA binding of NF-kappaB and pro-inflammatory gene expression were all rescued by over expression of beta-catenin, which shows that the anti-inflammatory effect of XAV939 is mediated by the modulation of beta-catenin, a central component of the WNT/beta-catenin pathway.	XAV939	27-33	catenin beta 1	Homo sapiens	166-178
30466341-7	2019	The suppressive effects of XAV939 on NF-kappaB signaling, target DNA binding of NF-kappaB and pro-inflammatory gene expression were all rescued by over expression of beta-catenin, which shows that the anti-inflammatory effect of XAV939 is mediated by the modulation of beta-catenin, a central component of the WNT/beta-catenin pathway.	XAV939	27-33	catenin beta 1	Homo sapiens	269-281
30466341-7	2019	The suppressive effects of XAV939 on NF-kappaB signaling, target DNA binding of NF-kappaB and pro-inflammatory gene expression were all rescued by over expression of beta-catenin, which shows that the anti-inflammatory effect of XAV939 is mediated by the modulation of beta-catenin, a central component of the WNT/beta-catenin pathway.	XAV939	27-33	catenin beta 1	Homo sapiens	269-281
30466341-7	2019	The suppressive effects of XAV939 on NF-kappaB signaling, target DNA binding of NF-kappaB and pro-inflammatory gene expression were all rescued by over expression of beta-catenin, which shows that the anti-inflammatory effect of XAV939 is mediated by the modulation of beta-catenin, a central component of the WNT/beta-catenin pathway.	XAV939	229-235	catenin beta 1	Homo sapiens	166-178
30466341-7	2019	The suppressive effects of XAV939 on NF-kappaB signaling, target DNA binding of NF-kappaB and pro-inflammatory gene expression were all rescued by over expression of beta-catenin, which shows that the anti-inflammatory effect of XAV939 is mediated by the modulation of beta-catenin, a central component of the WNT/beta-catenin pathway.	XAV939	229-235	catenin beta 1	Homo sapiens	269-281
30466341-7	2019	The suppressive effects of XAV939 on NF-kappaB signaling, target DNA binding of NF-kappaB and pro-inflammatory gene expression were all rescued by over expression of beta-catenin, which shows that the anti-inflammatory effect of XAV939 is mediated by the modulation of beta-catenin, a central component of the WNT/beta-catenin pathway.	XAV939	229-235	catenin beta 1	Homo sapiens	269-281
30466341-8	2019	Conclusion: The findings of this study showed that XAV939 exerts anti-inflammatory effects through the modulation of the Wnt/beta-catenin pathway.	XAV939	51-57	catenin beta 1	Homo sapiens	125-137
31186710-12	2019	Furthermore, the downregulation of SLC7A11 induced by XAV939 may also inhibit the development of NSCLC via the ferroptosis pathway.	XAV939	54-60	solute carrier family 7 member 11	Homo sapiens	35-42
31002351-5	2019	Additionally, TRIM52-induced cell proliferation and invasiveness, as well as the levels of cell cycle-associated proteins, were completely counteracted by the Wnt/beta-catenin inhibitor XAV939.	XAV939	186-192	catenin beta 1	Homo sapiens	163-175
31134047-11	2019	In addition, inhibition of the Wnt/beta-catenin pathway by XAV939 negated the effect of FKN overexpression, whereas activation of the Wnt/beta-catenin pathway by Ang II impaired the effect of the FKN knockout on EMT in HK-2 cells.	XAV939	59-65	chemokine (C-X3-C motif) ligand 1	Mus musculus	88-91
31191623-6	2019	Treatment with XAV-939, an inactivator of the Wnt/beta-catenin pathway, reduced the endogenous expression of miR-17-92 cluster.	XAV939	15-22	catenin beta 1	Gallus gallus	50-62
31191623-6	2019	Treatment with XAV-939, an inactivator of the Wnt/beta-catenin pathway, reduced the endogenous expression of miR-17-92 cluster.	XAV939	15-22	microRNA 1792	Gallus gallus	109-118
30360026-8	2019	On inhibition of beta-catenin by XAV939 and siRNA in BxPC3 cell line, invasiveness was significantly decreased (p < 0.01).	XAV939	33-39	catenin beta 1	Homo sapiens	17-29
28694128-9	2019	Furthermore, we found that ectopic expression of AXIN2 or pharmacological inhibition of beta-catenin by XAV-939 can attenuate the effect of miR-221-3p on cell proliferation in PASMC.	XAV939	104-111	catenin beta 1	Homo sapiens	88-100
28694128-9	2019	Furthermore, we found that ectopic expression of AXIN2 or pharmacological inhibition of beta-catenin by XAV-939 can attenuate the effect of miR-221-3p on cell proliferation in PASMC.	XAV939	104-111	microRNA 221	Homo sapiens	140-147
30690078-7	2019	Inhibition of beta-Catenin by XAV-939 markedly attenuates UBE2S-promoted cell growth.	XAV939	30-33	catenin beta 1	Homo sapiens	14-26
30690078-7	2019	Inhibition of beta-Catenin by XAV-939 markedly attenuates UBE2S-promoted cell growth.	XAV939	30-33	ubiquitin conjugating enzyme E2 S	Homo sapiens	58-63
30810286-8	2019	Treatment with the WNT/beta-catenin inhibitor XAV939 inhibited ING5-knockdown promoted proliferation, colony formation, migration, and invasion of lung cancer A549 cells, with increased phosphorylation of beta-catenin S33/37 and a decreased beta-catenin level.	XAV939	46-52	catenin beta 1	Homo sapiens	23-35
30810286-8	2019	Treatment with the WNT/beta-catenin inhibitor XAV939 inhibited ING5-knockdown promoted proliferation, colony formation, migration, and invasion of lung cancer A549 cells, with increased phosphorylation of beta-catenin S33/37 and a decreased beta-catenin level.	XAV939	46-52	inhibitor of growth family member 5	Homo sapiens	63-67
30810286-8	2019	Treatment with the WNT/beta-catenin inhibitor XAV939 inhibited ING5-knockdown promoted proliferation, colony formation, migration, and invasion of lung cancer A549 cells, with increased phosphorylation of beta-catenin S33/37 and a decreased beta-catenin level.	XAV939	46-52	catenin beta 1	Homo sapiens	205-217
30810286-8	2019	Treatment with the WNT/beta-catenin inhibitor XAV939 inhibited ING5-knockdown promoted proliferation, colony formation, migration, and invasion of lung cancer A549 cells, with increased phosphorylation of beta-catenin S33/37 and a decreased beta-catenin level.	XAV939	46-52	catenin beta 1	Homo sapiens	205-217
30810286-10	2019	Furthermore, XAV939 could inhibit the activation of both IL-6/STAT3 and PI3K/Akt signaling pathways.	XAV939	13-19	interleukin 6	Homo sapiens	57-61
30810286-10	2019	Furthermore, XAV939 could inhibit the activation of both IL-6/STAT3 and PI3K/Akt signaling pathways.	XAV939	13-19	signal transducer and activator of transcription 3	Homo sapiens	62-67
30886380-0	2019	The WNT/beta-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro.	XAV939	41-47	catenin beta 1	Homo sapiens	8-20
30886380-4	2019	Here, we evaluated the benefit(s) of the Wnt/beta-catenin signaling inhibitor XAV939 in the in vitro elimination of LNCaP prostate cancer cells when cocultured with lymphocytes from patients with localized biochemically recurrent prostate cancer (BRPCa).	XAV939	78-84	catenin beta 1	Homo sapiens	45-57
30886380-5	2019	We found that 5 microM XAV939 inhibited beta-catenin translocation to the nucleus in LNCaP cells and CD4+ BRPCa lymphocytes without affecting their proliferation and viability.	XAV939	23-29	catenin beta 1	Homo sapiens	40-52
30886380-5	2019	We found that 5 microM XAV939 inhibited beta-catenin translocation to the nucleus in LNCaP cells and CD4+ BRPCa lymphocytes without affecting their proliferation and viability.	XAV939	23-29	CD4 molecule	Homo sapiens	101-104
30809100-9	2019	Wnt-signaling blockade by Axin 1 rescue or pathway inhibitor XAV939 reversed AFP function, suggesting the potential therapeutic value of APGC.	XAV939	61-67	alpha fetoprotein	Homo sapiens	77-80
30718786-4	2019	We previously demonstrated that increasing the expression of the multifunctional scaffold protein Axis inhibition protein (Axin) by administration of the small molecule XAV939 enhances embryonic neurogenesis and affects social interaction behaviors.	XAV939	169-175	axin 1	Mus musculus	123-127
30544046-2	2019	Here, we showed that a 14-day culture of MSC-laden hyaluronic acid hydrogel in the presence of TGFbeta, followed by 7 days culture in TGFbeta-free medium, with the supplement of Wnt/beta-catenin inhibitor XAV939 from day 10-21, resulted in significantly reduced hypertrophy phenotype.	XAV939	205-211	catenin beta 1	Homo sapiens	182-194
30684559-8	2019	XAV939, a Wnt/beta-catenin pathway inhibitor, was introduced to confirm the involvement of Wnt/beta-catenin pathway in functions of LRP6.	XAV939	0-6	catenin beta 1	Homo sapiens	14-26
30684559-8	2019	XAV939, a Wnt/beta-catenin pathway inhibitor, was introduced to confirm the involvement of Wnt/beta-catenin pathway in functions of LRP6.	XAV939	0-6	LDL receptor related protein 6	Homo sapiens	132-136
30544046-5	2019	Further analysis showed that TGFbeta treatment time affected p38 expression, while exposure to XAV939 significantly inhibited P-Smad 1/5 level, which together resulted in decreased level of Runx2.	XAV939	95-101	SMAD family member 1	Homo sapiens	128-136
30544046-5	2019	Further analysis showed that TGFbeta treatment time affected p38 expression, while exposure to XAV939 significantly inhibited P-Smad 1/5 level, which together resulted in decreased level of Runx2.	XAV939	95-101	RUNX family transcription factor 2	Homo sapiens	190-195
30483745-7	2019	XAV-939, a small molecule that inhibits the Wnt/beta-catenin signaling pathway by facilitating beta-catenin degradation, lowered beta-catenin and cyclin D1 protein expression to an extent similar to AT-101.	XAV939	0-3	cyclin D1	Homo sapiens	146-155
30834083-6	2019	Moreover, the role of beta-catenin signaling in the osteogenic differentiation was detected by using beta-catenin signaling inhibitor XAV939.	XAV939	134-140	catenin beta 1	Homo sapiens	22-34
30834083-6	2019	Moreover, the role of beta-catenin signaling in the osteogenic differentiation was detected by using beta-catenin signaling inhibitor XAV939.	XAV939	134-140	catenin beta 1	Homo sapiens	101-113
30483745-7	2019	XAV-939, a small molecule that inhibits the Wnt/beta-catenin signaling pathway by facilitating beta-catenin degradation, lowered beta-catenin and cyclin D1 protein expression to an extent similar to AT-101.	XAV939	0-3	catenin beta 1	Homo sapiens	48-60
30483745-7	2019	XAV-939, a small molecule that inhibits the Wnt/beta-catenin signaling pathway by facilitating beta-catenin degradation, lowered beta-catenin and cyclin D1 protein expression to an extent similar to AT-101.	XAV939	0-3	catenin beta 1	Homo sapiens	95-107
30483745-7	2019	XAV-939, a small molecule that inhibits the Wnt/beta-catenin signaling pathway by facilitating beta-catenin degradation, lowered beta-catenin and cyclin D1 protein expression to an extent similar to AT-101.	XAV939	0-3	catenin beta 1	Homo sapiens	95-107
30678687-10	2019	Additionally, NUSAP1-induced cervical cancer cells metastasis and the cancer stem cell phenotype were abrogated with the Wnt/beta-catenin signaling inhibitor XAV-939 treatment.	XAV939	158-165	nucleolar and spindle associated protein 1	Homo sapiens	14-20
30678687-10	2019	Additionally, NUSAP1-induced cervical cancer cells metastasis and the cancer stem cell phenotype were abrogated with the Wnt/beta-catenin signaling inhibitor XAV-939 treatment.	XAV939	158-165	catenin beta 1	Homo sapiens	125-137
30678687-11	2019	Importantly, co-therapy of conventional treatment and XAV-939 will provide a novel and effective treatment for NUSAP1-ovexpressed cervical cancer patients.	XAV939	54-57	nucleolar and spindle associated protein 1	Homo sapiens	111-117
30389710-11	2019	In contrast, TRIM59 overexpression could increase cell proliferation, up-regulate Survivin, beta-catenin and c-myc, down-regulate Bax and Bim, and these effects could be blocked by XAV939, which is an inhibitor of Wnt/beta-catenin signaling pathway.	XAV939	181-187	tripartite motif containing 59	Homo sapiens	13-19
30389710-11	2019	In contrast, TRIM59 overexpression could increase cell proliferation, up-regulate Survivin, beta-catenin and c-myc, down-regulate Bax and Bim, and these effects could be blocked by XAV939, which is an inhibitor of Wnt/beta-catenin signaling pathway.	XAV939	181-187	catenin beta 1	Homo sapiens	92-104
30389710-11	2019	In contrast, TRIM59 overexpression could increase cell proliferation, up-regulate Survivin, beta-catenin and c-myc, down-regulate Bax and Bim, and these effects could be blocked by XAV939, which is an inhibitor of Wnt/beta-catenin signaling pathway.	XAV939	181-187	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	109-114
30389710-11	2019	In contrast, TRIM59 overexpression could increase cell proliferation, up-regulate Survivin, beta-catenin and c-myc, down-regulate Bax and Bim, and these effects could be blocked by XAV939, which is an inhibitor of Wnt/beta-catenin signaling pathway.	XAV939	181-187	BCL2 associated X, apoptosis regulator	Homo sapiens	130-133
30389710-11	2019	In contrast, TRIM59 overexpression could increase cell proliferation, up-regulate Survivin, beta-catenin and c-myc, down-regulate Bax and Bim, and these effects could be blocked by XAV939, which is an inhibitor of Wnt/beta-catenin signaling pathway.	XAV939	181-187	BCL2 like 11	Homo sapiens	138-141
30389710-11	2019	In contrast, TRIM59 overexpression could increase cell proliferation, up-regulate Survivin, beta-catenin and c-myc, down-regulate Bax and Bim, and these effects could be blocked by XAV939, which is an inhibitor of Wnt/beta-catenin signaling pathway.	XAV939	181-187	catenin beta 1	Homo sapiens	218-230
30483745-8	2019	XAV-939 alone resulted in G1/G0 phase arrest and further induced cell cycle arrest in combination with AT-101, suggesting that the beta-catenin/cyclin D1 signaling pathway mediated, at least in part, the cell cycle arrest induced by AT-101.	XAV939	0-7	catenin beta 1	Homo sapiens	131-143
30483745-8	2019	XAV-939 alone resulted in G1/G0 phase arrest and further induced cell cycle arrest in combination with AT-101, suggesting that the beta-catenin/cyclin D1 signaling pathway mediated, at least in part, the cell cycle arrest induced by AT-101.	XAV939	0-7	cyclin D1	Homo sapiens	144-153
30631044-6	2019	In addition, suppression of Wnt signaling by XAV-939 led to a marked suppression of the cell proliferation enhanced by CDX2 knockdown, whereas activation of this signaling by CHIR-99021 significantly enhanced the cell proliferation inhibited by CDX2 overexpression.	XAV939	45-52	caudal type homeobox 2	Homo sapiens	119-123
30466627-9	2018	Furthermore, XAV939, an inhibitor of beta-catenin, was used to treat HeLa cells and the results demonstrated that F5 inhibited proliferation and migration via the inhibition of the Wnt/beta-catenin pathway.	XAV939	13-19	catenin beta 1	Homo sapiens	37-49
30532256-2	2018	One strategy may be to use the tankyrase inhibitor XAV-939, which leads to Axin stabilisation and subsequent destruction of the beta-catenin complex and dephosphorylation of beta-catenin.	XAV939	51-58	axin 1	Homo sapiens	75-79
30532256-2	2018	One strategy may be to use the tankyrase inhibitor XAV-939, which leads to Axin stabilisation and subsequent destruction of the beta-catenin complex and dephosphorylation of beta-catenin.	XAV939	51-58	catenin beta 1	Homo sapiens	128-140
30532256-2	2018	One strategy may be to use the tankyrase inhibitor XAV-939, which leads to Axin stabilisation and subsequent destruction of the beta-catenin complex and dephosphorylation of beta-catenin.	XAV939	51-58	catenin beta 1	Homo sapiens	174-186
30532256-11	2018	Sox9 was induced during XAV-939 treatment but apparently not as a result of downregulation of beta-catenin signalling.	XAV939	24-27	SRY-box transcription factor 9	Homo sapiens	0-4
30532256-12	2018	XAV-939 was therefore able to prevent calcification of human VIC cultures, and XAV-939 treatment was accompanied by upregulation of active non-phospho-beta-catenin.	XAV939	79-82	catenin beta 1	Homo sapiens	151-163
30532256-13	2018	Although XAV-939 does not downregulate active beta-catenin, treatment with XAV-939 results in Sox9 upregulation that may prevent the calcification process.	XAV939	75-78	SRY-box transcription factor 9	Homo sapiens	94-98
30466627-9	2018	Furthermore, XAV939, an inhibitor of beta-catenin, was used to treat HeLa cells and the results demonstrated that F5 inhibited proliferation and migration via the inhibition of the Wnt/beta-catenin pathway.	XAV939	13-19	catenin beta 1	Homo sapiens	185-197
30185973-0	2018	Quantitative Proteomic Analysis of 2D and 3D Cultured Colorectal Cancer Cells: Profiling of Tankyrase Inhibitor XAV939-Induced Proteome.	XAV939	112-118	tankyrase	Homo sapiens	92-101
30323224-5	2018	Using XAV-939, a Wnt/beta-catenin inhibitor, we found that the effects of PHF19 on GBM cells were beta-catenin-dependent.	XAV939	6-13	catenin beta 1	Homo sapiens	21-33
30323224-5	2018	Using XAV-939, a Wnt/beta-catenin inhibitor, we found that the effects of PHF19 on GBM cells were beta-catenin-dependent.	XAV939	6-13	PHD finger protein 19	Homo sapiens	74-79
30323224-5	2018	Using XAV-939, a Wnt/beta-catenin inhibitor, we found that the effects of PHF19 on GBM cells were beta-catenin-dependent.	XAV939	6-13	catenin beta 1	Homo sapiens	98-110
30402858-9	2018	Rescue experiments indicated that XAV-939, the inhibitor of Wnt pathway, could partially reverse the increased proliferative and migratory changes in HUVECs induced by TUG1 overexpression.	XAV939	34-41	taurine up-regulated 1	Homo sapiens	168-172
30042033-11	2018	Besides, liraglutide induced an increase of beta-catenin, c-myc, and cyclin D1 levels, which could also be blocked in the presence of Xav939.	XAV939	134-140	catenin beta 1	Homo sapiens	44-56
30042033-11	2018	Besides, liraglutide induced an increase of beta-catenin, c-myc, and cyclin D1 levels, which could also be blocked in the presence of Xav939.	XAV939	134-140	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	58-63
30042033-11	2018	Besides, liraglutide induced an increase of beta-catenin, c-myc, and cyclin D1 levels, which could also be blocked in the presence of Xav939.	XAV939	134-140	cyclin D1	Homo sapiens	69-78
30548299-4	2018	Wnt/beta-catenin signaling pathway was inhibited by treatment with 20 muM of XAV-939 or activated by treatment with 20 mM of LiCl.	XAV939	77-84	catenin beta 1	Homo sapiens	4-16
30425532-8	2018	Besides, the beta-catenin inhibitor XAV939 blocked the enhanced cell growth, migration, and invasion caused by ARHGAP30 knockdown.	XAV939	36-42	catenin beta 1	Homo sapiens	13-25
30425532-8	2018	Besides, the beta-catenin inhibitor XAV939 blocked the enhanced cell growth, migration, and invasion caused by ARHGAP30 knockdown.	XAV939	36-42	Rho GTPase activating protein 30	Homo sapiens	111-119
30031230-11	2018	Suppression of beta-Catenin by siRNA or specific inhibitor XAV-939 markedly attenuated CBX1-mediated cell growth.	XAV939	59-66	chromobox 1	Homo sapiens	87-91
30260955-5	2018	Consistently, deletion of Tnks or blockage of TNKS activity with the inhibitor XAV939 significantly inhibits the growth of intestinal organoids.	XAV939	79-85	tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase	Mus musculus	46-50
30185973-6	2018	We also investigated the XAV939 (tankyrase inhibitor)-induced proteome to reveal factors involved in the 3D culture-selective growth inhibitory effect of XAV939 on SW480 cells.	XAV939	25-31	tankyrase	Homo sapiens	33-42
30185973-6	2018	We also investigated the XAV939 (tankyrase inhibitor)-induced proteome to reveal factors involved in the 3D culture-selective growth inhibitory effect of XAV939 on SW480 cells.	XAV939	154-160	tankyrase	Homo sapiens	33-42
30185973-7	2018	We identified novel XAV939-induced proteins, including gelsolin (a possible tumor suppressor) and lactate dehydrogenase A (a key enzyme of glycolysis), which were differentially expressed between 2D- and 3D-cultured SW480 cells.	XAV939	20-26	gelsolin	Homo sapiens	55-121
29516635-5	2018	Furthermore, XAV939, an inhibitor of beta-catenin, was used to treat HeLa cells and the results demonstrated that HMQ-T-F2 inhibited proliferation and migration via the inhibition of the Wnt/beta-catenin pathway.	XAV939	13-19	catenin beta 1	Homo sapiens	37-49
30126180-7	2018	The beta-catenin inhibitor, XAV939, also significantly inhibited the RLN2-induced cell invasions.	XAV939	28-34	catenin beta 1	Homo sapiens	4-16
30126180-7	2018	The beta-catenin inhibitor, XAV939, also significantly inhibited the RLN2-induced cell invasions.	XAV939	28-34	relaxin 2	Homo sapiens	69-73
29637602-9	2018	The results of HES1 downregulation coincide with RO and XAV effects on cell viability of OxaPt-treated cells.	XAV939	56-59	hes family bHLH transcription factor 1	Homo sapiens	15-19
29667777-8	2018	iPS-CM could also promote ILC proliferation through up-regulation of beta-catenin and its target proteins cyclin D1, c-Myc and survivin, but was inhibited by XAV939 (10 mumol/L).	XAV939	158-164	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	117-122
29949143-12	2018	Moreover, the inhibitory effect of MALAT1 down-regulation in cell invasion and migration was reversed by SKL2001 activating Wnt/beta-catenin signal pathway and enhanced by XAV939 inhibiting Wnt/beta-catenin signal pathway.	XAV939	172-178	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	35-41
29949143-12	2018	Moreover, the inhibitory effect of MALAT1 down-regulation in cell invasion and migration was reversed by SKL2001 activating Wnt/beta-catenin signal pathway and enhanced by XAV939 inhibiting Wnt/beta-catenin signal pathway.	XAV939	172-178	catenin beta 1	Homo sapiens	194-206
29669812-3	2018	Treatment of differentiated L6 myotubes with the small molecule tankyrase inhibitor XAV939 resulted in insulin resistance as determined by impaired insulin-stimulated glucose uptake.	XAV939	84-90	tankyrase	Homo sapiens	64-73
29669812-3	2018	Treatment of differentiated L6 myotubes with the small molecule tankyrase inhibitor XAV939 resulted in insulin resistance as determined by impaired insulin-stimulated glucose uptake.	XAV939	84-90	insulin	Homo sapiens	103-110
29669812-3	2018	Treatment of differentiated L6 myotubes with the small molecule tankyrase inhibitor XAV939 resulted in insulin resistance as determined by impaired insulin-stimulated glucose uptake.	XAV939	84-90	insulin	Homo sapiens	148-155
29805633-1	2018	The present study assessed the effects of the tankyrase (TNKS) small molecule inhibitor XAV939 on the proliferation and migration of lung adenocarcinoma A549 cells and the possible underlying mechanism.	XAV939	88-94	tankyrase	Homo sapiens	46-55
29805633-1	2018	The present study assessed the effects of the tankyrase (TNKS) small molecule inhibitor XAV939 on the proliferation and migration of lung adenocarcinoma A549 cells and the possible underlying mechanism.	XAV939	88-94	tankyrase	Homo sapiens	57-61
29805633-10	2018	The TNKS inhibitor XAV939 inhibited lung adenocarcinoma A549 cell proliferation and migration in vitro.	XAV939	19-25	tankyrase	Homo sapiens	4-8
29516635-5	2018	Furthermore, XAV939, an inhibitor of beta-catenin, was used to treat HeLa cells and the results demonstrated that HMQ-T-F2 inhibited proliferation and migration via the inhibition of the Wnt/beta-catenin pathway.	XAV939	13-19	catenin beta 1	Homo sapiens	191-203
29415892-4	2018	Mice underwent destabilization of the medial meniscus surgery and were treated by intra-articular injection with XAV-939, a small-molecule inhibitor of Wnt/beta-catenin signaling.	XAV939	113-120	catenin (cadherin associated protein), beta 1	Mus musculus	156-168
29562208-5	2018	In the present study, we found that XAV939-inhibition of canonical WNT signaling in skin of YAP2-5SA-DeltaC mice resulted in diminished beta-catenin activation, reduced keratinocyte proliferation, and a mitigation of the hyperplastic abnormalities in the interfollicular epidermis, signifying a canonical WNT ligand-dependent mechanism.	XAV939	36-42	wingless-type MMTV integration site family, member 16	Mus musculus	67-70
29562208-5	2018	In the present study, we found that XAV939-inhibition of canonical WNT signaling in skin of YAP2-5SA-DeltaC mice resulted in diminished beta-catenin activation, reduced keratinocyte proliferation, and a mitigation of the hyperplastic abnormalities in the interfollicular epidermis, signifying a canonical WNT ligand-dependent mechanism.	XAV939	36-42	catenin (cadherin associated protein), beta 1	Mus musculus	136-148
29562208-5	2018	In the present study, we found that XAV939-inhibition of canonical WNT signaling in skin of YAP2-5SA-DeltaC mice resulted in diminished beta-catenin activation, reduced keratinocyte proliferation, and a mitigation of the hyperplastic abnormalities in the interfollicular epidermis, signifying a canonical WNT ligand-dependent mechanism.	XAV939	36-42	wingless-type MMTV integration site family, member 16	Mus musculus	305-308
29268145-4	2018	XAV939 and SP600125,the inhibitors of the WNT/beta-catenin and JNK pathways, were further applied to verify the mechanism.	XAV939	0-6	catenin beta 1	Homo sapiens	46-58
29268145-4	2018	XAV939 and SP600125,the inhibitors of the WNT/beta-catenin and JNK pathways, were further applied to verify the mechanism.	XAV939	0-6	mitogen-activated protein kinase 8	Homo sapiens	63-66
29599817-8	2018	The mRNA expression levels of GSK3beta and DKK1 in the WYHZTL formula and XAV-939-treated group were significantly higher than those in the BLM group, while Wnt1, beta-catenin, TCF4, cyclin D1, survivin, VEGF, CTGF, FN1, collagen I/III were decreased.	XAV939	74-81	glycogen synthase kinase 3 beta	Mus musculus	30-38
29599817-8	2018	The mRNA expression levels of GSK3beta and DKK1 in the WYHZTL formula and XAV-939-treated group were significantly higher than those in the BLM group, while Wnt1, beta-catenin, TCF4, cyclin D1, survivin, VEGF, CTGF, FN1, collagen I/III were decreased.	XAV939	74-81	dickkopf WNT signaling pathway inhibitor 1	Mus musculus	43-47
29599817-8	2018	The mRNA expression levels of GSK3beta and DKK1 in the WYHZTL formula and XAV-939-treated group were significantly higher than those in the BLM group, while Wnt1, beta-catenin, TCF4, cyclin D1, survivin, VEGF, CTGF, FN1, collagen I/III were decreased.	XAV939	74-81	cyclin D1	Mus musculus	183-192
29599817-8	2018	The mRNA expression levels of GSK3beta and DKK1 in the WYHZTL formula and XAV-939-treated group were significantly higher than those in the BLM group, while Wnt1, beta-catenin, TCF4, cyclin D1, survivin, VEGF, CTGF, FN1, collagen I/III were decreased.	XAV939	74-81	baculoviral IAP repeat-containing 5	Mus musculus	194-202
29599817-8	2018	The mRNA expression levels of GSK3beta and DKK1 in the WYHZTL formula and XAV-939-treated group were significantly higher than those in the BLM group, while Wnt1, beta-catenin, TCF4, cyclin D1, survivin, VEGF, CTGF, FN1, collagen I/III were decreased.	XAV939	74-81	vascular endothelial growth factor A	Mus musculus	204-208
29599817-8	2018	The mRNA expression levels of GSK3beta and DKK1 in the WYHZTL formula and XAV-939-treated group were significantly higher than those in the BLM group, while Wnt1, beta-catenin, TCF4, cyclin D1, survivin, VEGF, CTGF, FN1, collagen I/III were decreased.	XAV939	74-81	cellular communication network factor 2	Mus musculus	210-214
29599817-8	2018	The mRNA expression levels of GSK3beta and DKK1 in the WYHZTL formula and XAV-939-treated group were significantly higher than those in the BLM group, while Wnt1, beta-catenin, TCF4, cyclin D1, survivin, VEGF, CTGF, FN1, collagen I/III were decreased.	XAV939	74-81	fibronectin 1	Mus musculus	216-219
29599817-9	2018	Compared with BLM group, the protein expression levels of GSK3beta and DKK1 in the WYHZTL formula and XAV-939-treated group were upregulated, while Wnt1, beta-catenin, cyclin D1, survivin, CTGF, FN1, collagen I/III were downregulated.	XAV939	102-105	glycogen synthase kinase 3 beta	Mus musculus	58-66
29599817-9	2018	Compared with BLM group, the protein expression levels of GSK3beta and DKK1 in the WYHZTL formula and XAV-939-treated group were upregulated, while Wnt1, beta-catenin, cyclin D1, survivin, CTGF, FN1, collagen I/III were downregulated.	XAV939	102-105	dickkopf WNT signaling pathway inhibitor 1	Mus musculus	71-75
29599817-10	2018	WYHZTL formula and XAV-939 could inhibit expression of Wnt1 and CTGF, but promoted DKK1 in serum.	XAV939	19-26	wingless-type MMTV integration site family, member 1	Mus musculus	55-59
29599817-10	2018	WYHZTL formula and XAV-939 could inhibit expression of Wnt1 and CTGF, but promoted DKK1 in serum.	XAV939	19-26	cellular communication network factor 2	Mus musculus	64-68
29599817-10	2018	WYHZTL formula and XAV-939 could inhibit expression of Wnt1 and CTGF, but promoted DKK1 in serum.	XAV939	19-26	dickkopf WNT signaling pathway inhibitor 1	Mus musculus	83-87
28337959-12	2018	XAV939, a tankyrase 1 inhibitor that could inhibit Wnt/beta-catenin signaling, significantly reversed the effects of miR-940 overexpression on cell migration and invasion.	XAV939	0-6	tankyrase	Homo sapiens	10-21
28337959-12	2018	XAV939, a tankyrase 1 inhibitor that could inhibit Wnt/beta-catenin signaling, significantly reversed the effects of miR-940 overexpression on cell migration and invasion.	XAV939	0-6	catenin beta 1	Homo sapiens	55-67
28337959-12	2018	XAV939, a tankyrase 1 inhibitor that could inhibit Wnt/beta-catenin signaling, significantly reversed the effects of miR-940 overexpression on cell migration and invasion.	XAV939	0-6	microRNA 940	Homo sapiens	117-124
29143549-7	2018	The treatment of MLE-12 cells with high glucose in the presence/absence of XAV939 or su5402 further proved that hyperglycaemia suppressed the expression of GATA6 and pro-SPC by activating Wnt signalling and induced the expression of decorin, alpha-SMA and TGF-beta by activating Fgf signalling.	XAV939	75-81	GATA binding protein 6	Mus musculus	156-161
29805736-6	2018	A Wnt signaling inhibitor (XAV939) down-regulated invasion and the expression of ASCL2, beta-catenin, and vimentin but up-regulated E-cadherin expression.	XAV939	27-33	achaete-scute family bHLH transcription factor 2	Mus musculus	81-86
29805736-6	2018	A Wnt signaling inhibitor (XAV939) down-regulated invasion and the expression of ASCL2, beta-catenin, and vimentin but up-regulated E-cadherin expression.	XAV939	27-33	catenin (cadherin associated protein), beta 1	Mus musculus	88-100
29805736-6	2018	A Wnt signaling inhibitor (XAV939) down-regulated invasion and the expression of ASCL2, beta-catenin, and vimentin but up-regulated E-cadherin expression.	XAV939	27-33	vimentin	Mus musculus	106-114
29805736-6	2018	A Wnt signaling inhibitor (XAV939) down-regulated invasion and the expression of ASCL2, beta-catenin, and vimentin but up-regulated E-cadherin expression.	XAV939	27-33	cadherin 1	Mus musculus	132-142
29099417-10	2018	CacyBP/SIP overexpression led to retarded proliferation, G1 arrest, and beta-catenin reduction, which could be abolished by lithium chloride, beta-catenin activator, and further enhanced by the Wnt inhibitor XAV-939.	XAV939	208-215	calcyclin binding protein	Homo sapiens	0-6
29099417-10	2018	CacyBP/SIP overexpression led to retarded proliferation, G1 arrest, and beta-catenin reduction, which could be abolished by lithium chloride, beta-catenin activator, and further enhanced by the Wnt inhibitor XAV-939.	XAV939	208-215	calcyclin binding protein	Homo sapiens	7-10
28877210-8	2017	Altogether, the present data indicate that XAV-939 and G007-LK Tankyrase inhibitors could suppress proliferation of hepatocellular carcinoma cells and downregulate YAP/TAZ by stabilizing AMOTL1 and AMOTL2 proteins, thus representing new potential anticancer drugs against hepatocellular carcinoma.	XAV939	43-46	tankyrase	Homo sapiens	63-72
29143549-7	2018	The treatment of MLE-12 cells with high glucose in the presence/absence of XAV939 or su5402 further proved that hyperglycaemia suppressed the expression of GATA6 and pro-SPC by activating Wnt signalling and induced the expression of decorin, alpha-SMA and TGF-beta by activating Fgf signalling.	XAV939	75-81	surfactant associated protein C	Mus musculus	166-173
29285071-8	2017	Furthermore, inhibiting beta-catenin signaling with XAV-939 suppressed the BMP-7-mediated changes.	XAV939	52-59	LOC100125986	Oryctolagus cuniculus	24-36
29285071-8	2017	Furthermore, inhibiting beta-catenin signaling with XAV-939 suppressed the BMP-7-mediated changes.	XAV939	52-59	bone morphogenetic protein 7	Oryctolagus cuniculus	75-80
29163677-9	2017	Using the Wnt/beta-catenin inhibitor XAV-939, the present study demonstrated that TRIM37-induced chemoresistance is partially dependent on the activation of the Wnt/beta-catenin signaling pathway.	XAV939	37-44	catenin beta 1	Homo sapiens	14-26
29163677-9	2017	Using the Wnt/beta-catenin inhibitor XAV-939, the present study demonstrated that TRIM37-induced chemoresistance is partially dependent on the activation of the Wnt/beta-catenin signaling pathway.	XAV939	37-44	tripartite motif containing 37	Homo sapiens	82-88
29163677-9	2017	Using the Wnt/beta-catenin inhibitor XAV-939, the present study demonstrated that TRIM37-induced chemoresistance is partially dependent on the activation of the Wnt/beta-catenin signaling pathway.	XAV939	37-44	catenin beta 1	Homo sapiens	165-177
29156556-7	2017	Furthermore, the mTORC1 and Wnt/beta-catenin pathway-specific antagonist rapamycin and XAV939 (3,5,7,8-tetrahydro-2-[4-(trifluoromethyl)]-4H -thiopyrano[4,3-d]pyrimidin-4-one) both suppressed the proliferation of IPEC-J2 cells overexpressing CDX2, and that the combination of rapamycin and XAV939 had an additive effect.	XAV939	87-93	catenin beta 1	Sus scrofa	32-44
29156556-7	2017	Furthermore, the mTORC1 and Wnt/beta-catenin pathway-specific antagonist rapamycin and XAV939 (3,5,7,8-tetrahydro-2-[4-(trifluoromethyl)]-4H -thiopyrano[4,3-d]pyrimidin-4-one) both suppressed the proliferation of IPEC-J2 cells overexpressing CDX2, and that the combination of rapamycin and XAV939 had an additive effect.	XAV939	87-93	caudal type homeobox 2	Sus scrofa	242-246
29156556-8	2017	Regardless of whether the cells were treated with rapamycin or XAV939 alone or in combination, both mTORC1 and Wnt/beta-catenin pathways were down-regulated, accompanied by a decrease in CDX2 expression.	XAV939	63-69	CREB regulated transcription coactivator 1	Mus musculus	100-106
29156556-8	2017	Regardless of whether the cells were treated with rapamycin or XAV939 alone or in combination, both mTORC1 and Wnt/beta-catenin pathways were down-regulated, accompanied by a decrease in CDX2 expression.	XAV939	63-69	catenin beta 1	Sus scrofa	115-127
29156556-8	2017	Regardless of whether the cells were treated with rapamycin or XAV939 alone or in combination, both mTORC1 and Wnt/beta-catenin pathways were down-regulated, accompanied by a decrease in CDX2 expression.	XAV939	63-69	caudal type homeobox 2	Sus scrofa	187-191
29217163-4	2017	XAV-939, a Wnt/beta-catenin pathway inhibitor, was used to inhibit the pathway.	XAV939	0-7	catenin beta 1	Homo sapiens	15-27
28337962-8	2017	Furthermore, XAV939 (inhibitor of beta-catenin) was used to treat MGC-803 cells, and we found that LINC00052 promoted proliferation and metastasis, possibly by activation of the Wnt/beta-catenin pathway.	XAV939	13-19	catenin beta 1	Homo sapiens	34-46
28337962-8	2017	Furthermore, XAV939 (inhibitor of beta-catenin) was used to treat MGC-803 cells, and we found that LINC00052 promoted proliferation and metastasis, possibly by activation of the Wnt/beta-catenin pathway.	XAV939	13-19	long intergenic non-protein coding RNA 52	Homo sapiens	99-108
28811361-4	2017	Here, inhibition of beta-catenin by siRNAs or a small-molecule inhibitor (XAV-939) resulted in sensitization of colorectal cancer cells to chemoradiotherapy.	XAV939	74-81	catenin beta 1	Homo sapiens	20-32
28830684-10	2017	XAV-939, an inhibitor of Wnt/beta-catenin signaling, partially reversed the pro-apoptotic effect of NE.	XAV939	0-7	Wnt family member 2	Rattus norvegicus	25-28
28830684-10	2017	XAV-939, an inhibitor of Wnt/beta-catenin signaling, partially reversed the pro-apoptotic effect of NE.	XAV939	0-7	catenin beta 1	Rattus norvegicus	29-41
28582278-8	2017	Importantly, treatment with Wnt/beta-catenin inhibitor XAV939 partly neutralized ADMSC-ex-induced antiapoptotic and prosurvival effects in H9c2 cells.	XAV939	55-61	Wnt family member 2	Rattus norvegicus	28-31
28582278-8	2017	Importantly, treatment with Wnt/beta-catenin inhibitor XAV939 partly neutralized ADMSC-ex-induced antiapoptotic and prosurvival effects in H9c2 cells.	XAV939	55-61	catenin beta 1	Rattus norvegicus	32-44
28877210-8	2017	Altogether, the present data indicate that XAV-939 and G007-LK Tankyrase inhibitors could suppress proliferation of hepatocellular carcinoma cells and downregulate YAP/TAZ by stabilizing AMOTL1 and AMOTL2 proteins, thus representing new potential anticancer drugs against hepatocellular carcinoma.	XAV939	43-46	Yes1 associated transcriptional regulator	Homo sapiens	164-167
28877210-8	2017	Altogether, the present data indicate that XAV-939 and G007-LK Tankyrase inhibitors could suppress proliferation of hepatocellular carcinoma cells and downregulate YAP/TAZ by stabilizing AMOTL1 and AMOTL2 proteins, thus representing new potential anticancer drugs against hepatocellular carcinoma.	XAV939	43-46	angiomotin like 1	Homo sapiens	187-193
28877210-8	2017	Altogether, the present data indicate that XAV-939 and G007-LK Tankyrase inhibitors could suppress proliferation of hepatocellular carcinoma cells and downregulate YAP/TAZ by stabilizing AMOTL1 and AMOTL2 proteins, thus representing new potential anticancer drugs against hepatocellular carcinoma.	XAV939	43-46	angiomotin like 2	Homo sapiens	198-204
28770967-9	2017	U2OS/ADM cells were further treated with si-beta-catenin and/or beta-catenin inhibitor XAV939.	XAV939	87-93	catenin beta 1	Homo sapiens	64-76
28536011-6	2017	XAV939, a beta-catenin inhibitor, attenuated WB cell malignant transformation due to Tg737 knockdown.	XAV939	0-6	catenin beta 1	Rattus norvegicus	10-22
28536011-6	2017	XAV939, a beta-catenin inhibitor, attenuated WB cell malignant transformation due to Tg737 knockdown.	XAV939	0-6	intraflagellar transport 88	Mus musculus	85-90
28525379-5	2017	The inhibition of beta-Catenin by siRNAs or XAV-939 significantly attenuates PBK-mediated malignant phenotypes.	XAV939	44-51	PDZ binding kinase	Homo sapiens	77-80
28628258-2	2017	Here, we investigated the effect of a specific Tankyrase inhibitor (XAV939) in follicular-luteal dynamics, and its possible relationship with ovarian vascular development.	XAV939	68-74	tankyrase	Rattus norvegicus	47-56
28770967-13	2017	Transfection of si-beta-catenin and XAV939 suppressed beta-catenin and Bcl-2 expression, and significantly enhanced ADM sensitivity and ADM-induced apoptosis.	XAV939	36-42	catenin beta 1	Homo sapiens	54-66
28770967-13	2017	Transfection of si-beta-catenin and XAV939 suppressed beta-catenin and Bcl-2 expression, and significantly enhanced ADM sensitivity and ADM-induced apoptosis.	XAV939	36-42	BCL2 apoptosis regulator	Homo sapiens	71-76
28900081-6	2017	Following the block of the Wnt/beta-catenin signaling pathway using the inhibitor XAV-939, the effects of miR-218 on the proliferation and apoptosis of human ovarian carcinoma cells were significantly suppressed.	XAV939	82-89	catenin beta 1	Homo sapiens	31-43
27624805-7	2017	Treatment with either XAV-939 or ICG-001 effectively inhibited activation of beta-catenin and downregulated mRNA expression of beta-catenin-targeted genes in TDI-asthmatic mice, paralleled by dramatically attenuated TDI-induced hyperresponsiveness and inflammation of the airway, alleviated airway goblet cell metaplasia and collagen deposition, decreased Th2 inflammation, as well as lower levels of TGFbeta1, VEGF, HMGB1, and IL-1beta.	XAV939	22-29	catenin (cadherin associated protein), beta 1	Mus musculus	77-89
28648006-3	2017	Real-time PCR and Western-blot were utilized to evaluate the variations of key factors in Wnt signaling pathways, while specific inhibitor of Wnt/beta-Catenin, XAV939 was used to block the Wnt signaling.	XAV939	160-166	catenin beta 1	Homo sapiens	146-158
28648006-8	2017	However, the specific inhibitor of Wnt/beta-Catenin, XAV939 completely abrogated Wnt/beta-Catenin signaling and the increase in ALP expression and activity induced by 0.5 Gy X-ray radiation.	XAV939	53-59	catenin beta 1	Homo sapiens	39-51
28648006-8	2017	However, the specific inhibitor of Wnt/beta-Catenin, XAV939 completely abrogated Wnt/beta-Catenin signaling and the increase in ALP expression and activity induced by 0.5 Gy X-ray radiation.	XAV939	53-59	catenin beta 1	Homo sapiens	85-97
28648006-8	2017	However, the specific inhibitor of Wnt/beta-Catenin, XAV939 completely abrogated Wnt/beta-Catenin signaling and the increase in ALP expression and activity induced by 0.5 Gy X-ray radiation.	XAV939	53-59	alkaline phosphatase, placental	Homo sapiens	128-131
28503382-19	2017	Coherently, the PARP inhibitor XAV939 improves myelination in vitro, ex vivo and in vivo.	XAV939	31-37	poly (ADP-ribose) polymerase family, member 1	Mus musculus	16-20
27624805-7	2017	Treatment with either XAV-939 or ICG-001 effectively inhibited activation of beta-catenin and downregulated mRNA expression of beta-catenin-targeted genes in TDI-asthmatic mice, paralleled by dramatically attenuated TDI-induced hyperresponsiveness and inflammation of the airway, alleviated airway goblet cell metaplasia and collagen deposition, decreased Th2 inflammation, as well as lower levels of TGFbeta1, VEGF, HMGB1, and IL-1beta.	XAV939	22-29	catenin (cadherin associated protein), beta 1	Mus musculus	127-139
27624805-7	2017	Treatment with either XAV-939 or ICG-001 effectively inhibited activation of beta-catenin and downregulated mRNA expression of beta-catenin-targeted genes in TDI-asthmatic mice, paralleled by dramatically attenuated TDI-induced hyperresponsiveness and inflammation of the airway, alleviated airway goblet cell metaplasia and collagen deposition, decreased Th2 inflammation, as well as lower levels of TGFbeta1, VEGF, HMGB1, and IL-1beta.	XAV939	22-29	transforming growth factor, beta 1	Mus musculus	401-409
27624805-7	2017	Treatment with either XAV-939 or ICG-001 effectively inhibited activation of beta-catenin and downregulated mRNA expression of beta-catenin-targeted genes in TDI-asthmatic mice, paralleled by dramatically attenuated TDI-induced hyperresponsiveness and inflammation of the airway, alleviated airway goblet cell metaplasia and collagen deposition, decreased Th2 inflammation, as well as lower levels of TGFbeta1, VEGF, HMGB1, and IL-1beta.	XAV939	22-29	vascular endothelial growth factor A	Mus musculus	411-415
27624805-7	2017	Treatment with either XAV-939 or ICG-001 effectively inhibited activation of beta-catenin and downregulated mRNA expression of beta-catenin-targeted genes in TDI-asthmatic mice, paralleled by dramatically attenuated TDI-induced hyperresponsiveness and inflammation of the airway, alleviated airway goblet cell metaplasia and collagen deposition, decreased Th2 inflammation, as well as lower levels of TGFbeta1, VEGF, HMGB1, and IL-1beta.	XAV939	22-29	high mobility group box 1	Mus musculus	417-422
27624805-7	2017	Treatment with either XAV-939 or ICG-001 effectively inhibited activation of beta-catenin and downregulated mRNA expression of beta-catenin-targeted genes in TDI-asthmatic mice, paralleled by dramatically attenuated TDI-induced hyperresponsiveness and inflammation of the airway, alleviated airway goblet cell metaplasia and collagen deposition, decreased Th2 inflammation, as well as lower levels of TGFbeta1, VEGF, HMGB1, and IL-1beta.	XAV939	22-29	interleukin 1 beta	Mus musculus	428-436
28485776-4	2017	Wnt inhibitor XAV 939 was administrated 30 min before anesthesia.	XAV939	14-21	Wnt family member 2	Rattus norvegicus	0-3
28177909-8	2017	Using Wnt signaling pathway inhibitor XAV-939 and activator LiCl, we detected the role of fibulin-4 in the Wnt/beta-catenin pathway and the relationship with epithelial to mesenchymal transition (EMT).	XAV939	38-45	EGF containing fibulin extracellular matrix protein 2	Homo sapiens	90-99
28093328-4	2017	Mechanistically, cinnamaldehyde imitated the suppressive effect of XAV939 on cell motility and EMT which could be impaired by LiCl.	XAV939	67-73	IL2 inducible T cell kinase	Homo sapiens	95-98
28352188-10	2017	Additionally, inactivation of the Wnt/beta-catenin pathway by XAV939 or si-beta-catenin suppressed cell proliferation and EMT.	XAV939	62-68	catenin beta 1	Homo sapiens	38-50
27445236-6	2016	Notably, inhibition of the Wnt/beta-catenin pathway by XAV939 partially blocked these effects.	XAV939	55-61	Wnt family member 2	Rattus norvegicus	27-30
28001384-6	2017	XAV939 is a promiscuous tankyrase inhibitor and a potent inhibitor of PARP1 in vitro and in cells, whereas IWR1 and AZ-6102 are tankyrase selective.	XAV939	0-6	tankyrase	Homo sapiens	24-33
28001384-6	2017	XAV939 is a promiscuous tankyrase inhibitor and a potent inhibitor of PARP1 in vitro and in cells, whereas IWR1 and AZ-6102 are tankyrase selective.	XAV939	0-6	poly(ADP-ribose) polymerase 1	Homo sapiens	70-75
27840407-7	2017	The neurite outgrowth-promoting effect of ARDD in neuronal cells was abolished by pretreatment with the specific ERK1/2 inhibitor PD98059, but was partially reversed by XAV939, an inhibitor of the Wnt/beta-catenin pathway.	XAV939	169-175	wingless-type MMTV integration site family, member 3A	Mus musculus	197-200
28758111-5	2017	Both LC3II/LC3I and beta-catenin were enhanced in the MNT group, while XAV939 (a beta-catenin inhibitor) decreased the expression of nuclear erythroid-related factor 2 (Nrf2) and LC3II/LC3I.	XAV939	71-77	catenin beta 1	Rattus norvegicus	81-93
28758111-5	2017	Both LC3II/LC3I and beta-catenin were enhanced in the MNT group, while XAV939 (a beta-catenin inhibitor) decreased the expression of nuclear erythroid-related factor 2 (Nrf2) and LC3II/LC3I.	XAV939	71-77	NFE2 like bZIP transcription factor 2	Rattus norvegicus	133-167
28758111-5	2017	Both LC3II/LC3I and beta-catenin were enhanced in the MNT group, while XAV939 (a beta-catenin inhibitor) decreased the expression of nuclear erythroid-related factor 2 (Nrf2) and LC3II/LC3I.	XAV939	71-77	NFE2 like bZIP transcription factor 2	Rattus norvegicus	169-173
29035884-12	2017	Pretreatment with MAPK inhibitors or the Wnt/beta-catenin inhibitor XAV939 blocked the protective effects of quercetin against LPS-induced apoptosis and the inhibition of osteoblast differentiation.	XAV939	68-74	catenin (cadherin associated protein), beta 1	Mus musculus	45-57
27629364-5	2016	Inhibition of beta-catenin/p300 interactions using IQ-1 or inhibition of tankyrase 1/2 using XAV-939 had considerably less effect.	XAV939	93-96	tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase	Mus musculus	73-84
27909726-10	2017	XAV-939, an inhibitor of beta-catenin signaling, markedly inhibited the migration and invasion of glioma cells, suggesting that beta-catenin may be associated with miR-21- and Sox2-induced invasion of glioma cells.	XAV939	0-7	catenin beta 1	Homo sapiens	25-37
27909726-10	2017	XAV-939, an inhibitor of beta-catenin signaling, markedly inhibited the migration and invasion of glioma cells, suggesting that beta-catenin may be associated with miR-21- and Sox2-induced invasion of glioma cells.	XAV939	0-7	catenin beta 1	Homo sapiens	128-140
27909726-10	2017	XAV-939, an inhibitor of beta-catenin signaling, markedly inhibited the migration and invasion of glioma cells, suggesting that beta-catenin may be associated with miR-21- and Sox2-induced invasion of glioma cells.	XAV939	0-7	microRNA 21	Homo sapiens	164-170
27909726-10	2017	XAV-939, an inhibitor of beta-catenin signaling, markedly inhibited the migration and invasion of glioma cells, suggesting that beta-catenin may be associated with miR-21- and Sox2-induced invasion of glioma cells.	XAV939	0-7	SRY-box transcription factor 2	Homo sapiens	176-180
28101169-7	2016	Furthermore, inhibition of beta-catenin signaling by XAV-939 effectively reversed cisplatin chemoresistance in SKOV3/DDP cells.	XAV939	53-60	catenin beta 1	Homo sapiens	27-39
27445236-6	2016	Notably, inhibition of the Wnt/beta-catenin pathway by XAV939 partially blocked these effects.	XAV939	55-61	catenin beta 1	Rattus norvegicus	31-43
27226553-5	2016	Furthermore, the mechanistic view that the proliferative function of Crlz-1 is caused by relaying Wnt/beta-catenin to pre-B cell receptor signaling pathways through the regulation of Runx/CBFbeta heterodimerization was also verified by employing niclosamide, XAV939, and LiCl as Wnt inhibitors and activator, respectively.	XAV939	259-265	UTP3 small subunit processome component	Homo sapiens	69-75
29786210-5	2016	Meanwhile, the beta-catenin inhibitors XAV-939 (0, 0.1, and 1.0 mumol/L) was added in group B; at 2 weeks after osteogenic and adipogenic induction, the gene and protein expressions of collagen type I (COL I), osteocalcin (OCN), and peroxisome proliferator activated receptor gamma 2 (PPARgamma-2) were detected by real time PCR and Western blot.	XAV939	39-42	LOC100125986	Oryctolagus cuniculus	15-27
27575480-6	2016	By the engagement of Wnt/beta-catenin pathway"s inhibitor (XAV-939), the protective effects of FDP-Sr on osteoblastic differentiation against oxidative stress were repressed along with inhibited wnt/beta-catenin signaling and reduced mRNA and protein levels of Runx2 and OPG.	XAV939	59-66	catenin (cadherin associated protein), beta 1	Mus musculus	25-37
27575480-6	2016	By the engagement of Wnt/beta-catenin pathway"s inhibitor (XAV-939), the protective effects of FDP-Sr on osteoblastic differentiation against oxidative stress were repressed along with inhibited wnt/beta-catenin signaling and reduced mRNA and protein levels of Runx2 and OPG.	XAV939	59-66	otoraplin	Mus musculus	95-98
27575480-6	2016	By the engagement of Wnt/beta-catenin pathway"s inhibitor (XAV-939), the protective effects of FDP-Sr on osteoblastic differentiation against oxidative stress were repressed along with inhibited wnt/beta-catenin signaling and reduced mRNA and protein levels of Runx2 and OPG.	XAV939	59-66	catenin (cadherin associated protein), beta 1	Mus musculus	199-211
27575480-6	2016	By the engagement of Wnt/beta-catenin pathway"s inhibitor (XAV-939), the protective effects of FDP-Sr on osteoblastic differentiation against oxidative stress were repressed along with inhibited wnt/beta-catenin signaling and reduced mRNA and protein levels of Runx2 and OPG.	XAV939	59-66	runt related transcription factor 2	Mus musculus	261-266
27575480-6	2016	By the engagement of Wnt/beta-catenin pathway"s inhibitor (XAV-939), the protective effects of FDP-Sr on osteoblastic differentiation against oxidative stress were repressed along with inhibited wnt/beta-catenin signaling and reduced mRNA and protein levels of Runx2 and OPG.	XAV939	59-66	tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)	Mus musculus	271-274
27613837-8	2016	However, blockade of beta-catenin by XAV939 (tankyrase inhibitor leading to beta-catenin degradation) did not synergize with p53 activation aiming to cell apoptosis as was the case with integrin antagonists.	XAV939	37-43	catenin beta 1	Homo sapiens	21-33
27373314-8	2016	Additionally, mechanistic investigation revealed that elevated Fzd2 expression activated canonical Wnt signaling and was blocked by canonical Wnt signaling inhibitor XAV939.	XAV939	166-172	frizzled class receptor 2	Homo sapiens	63-67
26970306-7	2016	Inhibition of the Wnt/beta-catenin pathway by the specific inhibitor XAV939 markedly attenuated Ang II-induced cardiomyocyte hypertrophy.	XAV939	69-75	catenin beta 1	Rattus norvegicus	22-34
27033953-8	2016	The mechanistic action of the cell model was further confirmed with a nude mouse animal model in which xenograft tumors induced by cNrf2 were nearly completely suppressed by the proteasomal inhibitor carfilzomib or the beta-catenin inhibitor XAV939.	XAV939	242-248	catenin beta 1	Homo sapiens	219-231
27371840-3	2016	The activated level of beta-catenin in the cells after cultivated with Ad-BMP9 and different concentrations of beta-catenin specific inhibitor XAV-939 was detected by Western blotting.	XAV939	143-150	catenin (cadherin associated protein), beta 1	Mus musculus	23-35
27371840-3	2016	The activated level of beta-catenin in the cells after cultivated with Ad-BMP9 and different concentrations of beta-catenin specific inhibitor XAV-939 was detected by Western blotting.	XAV939	143-150	catenin (cadherin associated protein), beta 1	Mus musculus	111-123
27371840-7	2016	After XAV-939 inhibited the activity of beta-catenin, the expressions of MEF2C, GATA4, Cx43, cTnT in C3H10T1/2 cells induced by BMP9 were significantly suppressed.	XAV939	6-13	catenin (cadherin associated protein), beta 1	Mus musculus	40-52
27371840-7	2016	After XAV-939 inhibited the activity of beta-catenin, the expressions of MEF2C, GATA4, Cx43, cTnT in C3H10T1/2 cells induced by BMP9 were significantly suppressed.	XAV939	6-13	myocyte enhancer factor 2C	Mus musculus	73-78
27371840-7	2016	After XAV-939 inhibited the activity of beta-catenin, the expressions of MEF2C, GATA4, Cx43, cTnT in C3H10T1/2 cells induced by BMP9 were significantly suppressed.	XAV939	6-13	GATA binding protein 4	Mus musculus	80-85
27371840-7	2016	After XAV-939 inhibited the activity of beta-catenin, the expressions of MEF2C, GATA4, Cx43, cTnT in C3H10T1/2 cells induced by BMP9 were significantly suppressed.	XAV939	6-13	gap junction protein, alpha 1	Mus musculus	87-91
27371840-7	2016	After XAV-939 inhibited the activity of beta-catenin, the expressions of MEF2C, GATA4, Cx43, cTnT in C3H10T1/2 cells induced by BMP9 were significantly suppressed.	XAV939	6-13	troponin T2, cardiac	Mus musculus	93-97
27371840-7	2016	After XAV-939 inhibited the activity of beta-catenin, the expressions of MEF2C, GATA4, Cx43, cTnT in C3H10T1/2 cells induced by BMP9 were significantly suppressed.	XAV939	6-13	growth differentiation factor 2	Mus musculus	128-132
27144834-3	2016	The tankyrase inhibitor, XAV939, identified in a screen for inhibitors of TEAD transcriptional activity, phenocopied these effects independently of its other known functions by stabilizing angiomotin and sequestering YAP in the cytosol.	XAV939	25-31	tankyrase	Homo sapiens	4-13
27144834-3	2016	The tankyrase inhibitor, XAV939, identified in a screen for inhibitors of TEAD transcriptional activity, phenocopied these effects independently of its other known functions by stabilizing angiomotin and sequestering YAP in the cytosol.	XAV939	25-31	Yes1 associated transcriptional regulator	Homo sapiens	217-220
26970306-7	2016	Inhibition of the Wnt/beta-catenin pathway by the specific inhibitor XAV939 markedly attenuated Ang II-induced cardiomyocyte hypertrophy.	XAV939	69-75	angiotensinogen	Rattus norvegicus	96-102
26820603-8	2016	Collectively, we show for the first time that the WNT signaling pathway inhibitor XAV939 was able to significantly increase the apoptosis induced by 5-FU/DDP, accompanied by the protein expression level alternation of beta-catenin, Axin and CSC markers in colon cancer cells.	XAV939	82-88	catenin beta 1	Homo sapiens	218-230
27007150-5	2016	The xenograft lung tumor nodules induced by DDX3-overexpressing T84 stable clone were nearly suppressed by the inhibitor of AKT (perifosine) or beta-catenin (XAV939).	XAV939	158-164	DEAD-box helicase 3 X-linked	Homo sapiens	44-48
27007150-5	2016	The xenograft lung tumor nodules induced by DDX3-overexpressing T84 stable clone were nearly suppressed by the inhibitor of AKT (perifosine) or beta-catenin (XAV939).	XAV939	158-164	catenin beta 1	Homo sapiens	144-156
27029901-7	2016	Furthermore, inhibition of the Wnt/beta-catenin signaling pathway by XAV939, a Wnt/beta-catenin signaling inhibitor, contributed to proliferation inhibition and apoptosis induction in NSCLC A549 cells.	XAV939	69-75	catenin beta 1	Homo sapiens	35-47
27029901-7	2016	Furthermore, inhibition of the Wnt/beta-catenin signaling pathway by XAV939, a Wnt/beta-catenin signaling inhibitor, contributed to proliferation inhibition and apoptosis induction in NSCLC A549 cells.	XAV939	69-75	catenin beta 1	Homo sapiens	83-95
26820603-8	2016	Collectively, we show for the first time that the WNT signaling pathway inhibitor XAV939 was able to significantly increase the apoptosis induced by 5-FU/DDP, accompanied by the protein expression level alternation of beta-catenin, Axin and CSC markers in colon cancer cells.	XAV939	82-88	axin 1	Homo sapiens	232-236
26096038-6	2015	Intrathecal application of XAV939, which acts as an inhibitor of Wnt signaling, significantly decreased the expression levels of active beta-catenin, and attenuated the rat behavioral responses to thermal and mechanical pain stimuli.	XAV939	27-33	Wnt family member 2	Rattus norvegicus	65-68
27150989-4	2016	RESULTS: 20 micromol/L XAV-939 and 20 mmol/L LiCl could effectively inhibit and activate Wnt signalling pathway of HL-60 cells respectively, could significantly down- and up-regulate the expression of cyclinD1, TCF1 and c-Jun genes (P < 0.05) and proteins (P < 0.05); moreover, the number of CD10(+) HL-60 cells in these conditions was below 1%, no early apoptosis of HL-60 cells was found.	XAV939	23-26	cyclin D1	Homo sapiens	201-209
27150989-4	2016	RESULTS: 20 micromol/L XAV-939 and 20 mmol/L LiCl could effectively inhibit and activate Wnt signalling pathway of HL-60 cells respectively, could significantly down- and up-regulate the expression of cyclinD1, TCF1 and c-Jun genes (P < 0.05) and proteins (P < 0.05); moreover, the number of CD10(+) HL-60 cells in these conditions was below 1%, no early apoptosis of HL-60 cells was found.	XAV939	23-26	transcription factor 7	Homo sapiens	211-215
27150989-4	2016	RESULTS: 20 micromol/L XAV-939 and 20 mmol/L LiCl could effectively inhibit and activate Wnt signalling pathway of HL-60 cells respectively, could significantly down- and up-regulate the expression of cyclinD1, TCF1 and c-Jun genes (P < 0.05) and proteins (P < 0.05); moreover, the number of CD10(+) HL-60 cells in these conditions was below 1%, no early apoptosis of HL-60 cells was found.	XAV939	23-26	Jun proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	220-225
27150989-4	2016	RESULTS: 20 micromol/L XAV-939 and 20 mmol/L LiCl could effectively inhibit and activate Wnt signalling pathway of HL-60 cells respectively, could significantly down- and up-regulate the expression of cyclinD1, TCF1 and c-Jun genes (P < 0.05) and proteins (P < 0.05); moreover, the number of CD10(+) HL-60 cells in these conditions was below 1%, no early apoptosis of HL-60 cells was found.	XAV939	23-26	membrane metalloendopeptidase	Homo sapiens	298-302
27352380-4	2016	The signaling pathway downstream of EGF was characterized by using the Wnt/beta-catenin signaling inhibitor, XAV-939.	XAV939	109-116	Wnt family member 10B	Homo sapiens	71-74
27352380-4	2016	The signaling pathway downstream of EGF was characterized by using the Wnt/beta-catenin signaling inhibitor, XAV-939.	XAV939	109-116	catenin beta 1	Homo sapiens	75-87
27352380-8	2016	Inhibition of Wnt/beta-catenin signaling by XAV-939 significantly reduced the basal and EGF-enhanced proliferation and migration of ORS cells.	XAV939	44-51	Wnt family member 10B	Homo sapiens	14-17
27352380-8	2016	Inhibition of Wnt/beta-catenin signaling by XAV-939 significantly reduced the basal and EGF-enhanced proliferation and migration of ORS cells.	XAV939	44-51	catenin beta 1	Homo sapiens	18-30
26544726-5	2015	Despite the low potency of SMA against tankyrase activity (IC50 of 50.1 muM and 15.5 muM for tankyrase 1 and 2, respectively) compared to XAV939 (IC50 of 11 nM for tankyrase 1), a selective and potent tankyrase inhibitor, SMA had strong inhibitory effects on beta-catenin-dependent TCF/LEF1 transcriptional activity (IC50 of 39.8 nM), which were similar to that of XAV939 (IC50 of 28.1 nM).	XAV939	365-371	survival of motor neuron 1, telomeric	Homo sapiens	27-30
26918728-7	2016	Furthermore, pharmacological inhibition of GSK-3beta using LiCl impaired the effect of AQP3 knockdown in CSCs, whereas the inhibition of the Wnt/beta-catenin pathway by XAV939 blocked the effect of AQP3 overexpression.	XAV939	169-175	catenin beta 1	Homo sapiens	145-157
26918728-7	2016	Furthermore, pharmacological inhibition of GSK-3beta using LiCl impaired the effect of AQP3 knockdown in CSCs, whereas the inhibition of the Wnt/beta-catenin pathway by XAV939 blocked the effect of AQP3 overexpression.	XAV939	169-175	aquaporin 3 (Gill blood group)	Homo sapiens	198-202
26518726-4	2016	We report here that while the activities of the four human sirtuin isoforms SIRT1, SIRT2, SIRT3 and SIRT6 are blocked by sirtuin inhibitor Ex527 in vitro, they are unaffected by the seven clinical and commonly used PARP inhibitors niraparib, olaparib, rucaparib, talazoparib, veliparib, PJ34, and XAV939.	XAV939	297-303	sirtuin 1	Homo sapiens	76-81
26518726-4	2016	We report here that while the activities of the four human sirtuin isoforms SIRT1, SIRT2, SIRT3 and SIRT6 are blocked by sirtuin inhibitor Ex527 in vitro, they are unaffected by the seven clinical and commonly used PARP inhibitors niraparib, olaparib, rucaparib, talazoparib, veliparib, PJ34, and XAV939.	XAV939	297-303	sirtuin 2	Homo sapiens	83-88
26518726-4	2016	We report here that while the activities of the four human sirtuin isoforms SIRT1, SIRT2, SIRT3 and SIRT6 are blocked by sirtuin inhibitor Ex527 in vitro, they are unaffected by the seven clinical and commonly used PARP inhibitors niraparib, olaparib, rucaparib, talazoparib, veliparib, PJ34, and XAV939.	XAV939	297-303	sirtuin 3	Homo sapiens	90-95
26518726-4	2016	We report here that while the activities of the four human sirtuin isoforms SIRT1, SIRT2, SIRT3 and SIRT6 are blocked by sirtuin inhibitor Ex527 in vitro, they are unaffected by the seven clinical and commonly used PARP inhibitors niraparib, olaparib, rucaparib, talazoparib, veliparib, PJ34, and XAV939.	XAV939	297-303	sirtuin 6	Homo sapiens	100-105
26897030-4	2016	METHODS: Fibroblasts from primary culture of skin lesions of SSc patients were exposed to rat medicated sera containing WYHZTL or XAV939, a small-molecule inhibitor of both tankyrase 1/2 and Wnt/beta-catenin pathway.	XAV939	130-136	Wnt family member 2	Rattus norvegicus	173-194
26900328-12	2016	Inhibition of beta-catenin by XAV939, but not the nuclear factor kappa B inhibitor, Bay 11-7082, prevented TNF-alpha-induced VEGF upregulation.	XAV939	30-36	catenin (cadherin associated protein), beta 1	Mus musculus	14-26
26900328-12	2016	Inhibition of beta-catenin by XAV939, but not the nuclear factor kappa B inhibitor, Bay 11-7082, prevented TNF-alpha-induced VEGF upregulation.	XAV939	30-36	tumor necrosis factor	Mus musculus	107-116
26900328-12	2016	Inhibition of beta-catenin by XAV939, but not the nuclear factor kappa B inhibitor, Bay 11-7082, prevented TNF-alpha-induced VEGF upregulation.	XAV939	30-36	vascular endothelial growth factor A	Mus musculus	125-129
26341496-7	2016	In vitro and in vivo, HOTAIR induced cellular resistance to cisplatin by activating the wnt/beta-catenin pathway, which could be reversed by pre-treatment with the wnt/beta-catenin inhibitor, XAV939.	XAV939	192-198	HOX transcript antisense RNA	Homo sapiens	22-28
26341496-7	2016	In vitro and in vivo, HOTAIR induced cellular resistance to cisplatin by activating the wnt/beta-catenin pathway, which could be reversed by pre-treatment with the wnt/beta-catenin inhibitor, XAV939.	XAV939	192-198	catenin beta 1	Homo sapiens	92-104
26341496-7	2016	In vitro and in vivo, HOTAIR induced cellular resistance to cisplatin by activating the wnt/beta-catenin pathway, which could be reversed by pre-treatment with the wnt/beta-catenin inhibitor, XAV939.	XAV939	192-198	catenin beta 1	Homo sapiens	168-180
26760502-11	2016	These effects of NaHS on fibronectin, E-cadherin and TbetaR I were abolished by the ERK inhibitor U0126 or beta-catenin inhibitor XAV939, or beta-catenin siRNA interference.	XAV939	130-136	fibronectin 1	Homo sapiens	25-36
26760502-11	2016	These effects of NaHS on fibronectin, E-cadherin and TbetaR I were abolished by the ERK inhibitor U0126 or beta-catenin inhibitor XAV939, or beta-catenin siRNA interference.	XAV939	130-136	transforming growth factor beta receptor 1	Homo sapiens	53-61
26760502-11	2016	These effects of NaHS on fibronectin, E-cadherin and TbetaR I were abolished by the ERK inhibitor U0126 or beta-catenin inhibitor XAV939, or beta-catenin siRNA interference.	XAV939	130-136	catenin beta 1	Homo sapiens	107-119
26096038-6	2015	Intrathecal application of XAV939, which acts as an inhibitor of Wnt signaling, significantly decreased the expression levels of active beta-catenin, and attenuated the rat behavioral responses to thermal and mechanical pain stimuli.	XAV939	27-33	catenin beta 1	Rattus norvegicus	136-148
25428393-7	2015	Furthermore, the inhibition of the Wnt/beta-catenin pathway by XAV939 offset the effects of PRRX1 overexpression.	XAV939	63-69	catenin beta 1	Homo sapiens	39-51
25382668-8	2015	Notably, the application of XAV939, an inhibitor of WNT/beta-catenin signaling pathway, ameliorated the effect of TCDD on cellular beta-catenin level, ROS production, cellular oxidative damage and premature senescence in astrocytes.	XAV939	28-34	catenin beta 1	Homo sapiens	56-68
25382668-8	2015	Notably, the application of XAV939, an inhibitor of WNT/beta-catenin signaling pathway, ameliorated the effect of TCDD on cellular beta-catenin level, ROS production, cellular oxidative damage and premature senescence in astrocytes.	XAV939	28-34	catenin beta 1	Homo sapiens	131-143
25835728-5	2015	In this study, we used the small molecule XAV939, a potent ARTD-5 inhibitor with a slight affinity for ARTD-1, in different human MB cell lines.	XAV939	42-48	tankyrase	Homo sapiens	59-65
25835728-5	2015	In this study, we used the small molecule XAV939, a potent ARTD-5 inhibitor with a slight affinity for ARTD-1, in different human MB cell lines.	XAV939	42-48	poly(ADP-ribose) polymerase 1	Homo sapiens	103-109
25520007-6	2015	dDAVP-induced AQP2 upregulation was attenuated in mpkCCDc14 cells under the tankyrase inhibition by XAV939 treatment or small interfering (si) RNA knockdown.	XAV939	100-106	aquaporin 2	Mus musculus	14-18
25384171-3	2015	METHODS AND RESULTS: We found that EGFR-mutated NSCLC cell lines exhibited a high expression level of beta-Catenin, compared with cell lines with the wild-type EGFR gene, and XAV939 (a beta-Catenin inhibitor) enhanced the sensitivities to EGFR-TKI in EGFR-mutated NSCLC cell lines.	XAV939	175-181	epidermal growth factor receptor	Homo sapiens	35-39
26072169-11	2015	Importantly, inhibition of the Wnt/beta-catenin pathway by XAV 939, which promotes degradation of beta-catenin, significantly abrogated the pro-invasion effects of irradiation.	XAV939	59-62	catenin beta 1	Homo sapiens	35-47
26072169-11	2015	Importantly, inhibition of the Wnt/beta-catenin pathway by XAV 939, which promotes degradation of beta-catenin, significantly abrogated the pro-invasion effects of irradiation.	XAV939	59-62	catenin beta 1	Homo sapiens	98-110
26072169-12	2015	Mechanistically, XAV 939 suppressed ionizing radiation-triggered up-regulation of MMP-2 and MMP-9, and inhibited the activities of these gelatinases.	XAV939	17-20	matrix metallopeptidase 2	Homo sapiens	82-87
26072169-12	2015	Mechanistically, XAV 939 suppressed ionizing radiation-triggered up-regulation of MMP-2 and MMP-9, and inhibited the activities of these gelatinases.	XAV939	17-20	matrix metallopeptidase 9	Homo sapiens	92-97
25711857-5	2015	We observed that zebrafish embryos exposed to the beta-catenin inhibitor XAV939 display effects phenocopying those of the dioxin-like 3,3",4,4",5-pentachlorobiphenyl (PCB126).	XAV939	73-79	catenin (cadherin-associated protein), beta 1	Danio rerio	50-62
25948195-0	2015	[Antiproliferative Effect of Specific Inhibitor XAV939 for beta-catenin on MCL Jeko-1 Cells].	XAV939	48-54	catenin beta 1	Homo sapiens	59-71
25948195-0	2015	[Antiproliferative Effect of Specific Inhibitor XAV939 for beta-catenin on MCL Jeko-1 Cells].	XAV939	48-54	C-type lectin domain family 4 member D	Homo sapiens	75-78
25948195-1	2015	OBJECTIVE: To investigate the effect of short hairpin RNA (shRNA) and XAV939, a specific inhibitor for beta-catenin, on growth and apoptosis of mantle cell lymphoma(MCL) Jeko-1 cell line.	XAV939	70-76	catenin beta 1	Homo sapiens	103-115
25948195-1	2015	OBJECTIVE: To investigate the effect of short hairpin RNA (shRNA) and XAV939, a specific inhibitor for beta-catenin, on growth and apoptosis of mantle cell lymphoma(MCL) Jeko-1 cell line.	XAV939	70-76	C-type lectin domain family 4 member D	Homo sapiens	165-168
25266063-7	2015	Ectopic expression of a degradation-resistant beta-catenin mutant enhances neuroblastoma cell viability and inhibition of beta-catenin with XAV939 prevented PGE2 -induced cell viability.	XAV939	140-146	catenin beta 1	Homo sapiens	122-134
25428393-7	2015	Furthermore, the inhibition of the Wnt/beta-catenin pathway by XAV939 offset the effects of PRRX1 overexpression.	XAV939	63-69	paired related homeobox 1	Homo sapiens	92-97
25426938-6	2014	In addition, the Wnt/beta-catenin pathway inhibitor XAV939 significantly inhibited the anti-apoptotic activities of PAC1-CHO.	XAV939	52-58	adenylate cyclase activating polypeptide 1 receptor 1	Mus musculus	116-120
25593505-11	2014	Treatment of the cells with the beta-catenin inhibitor XAV939 resulted in decreased expression of nuclear beta-catenin, VEGF levels, pBcl-2, and EMT proteins, as well as increased mitochondrial depolarization.	XAV939	55-61	catenin beta 1	Homo sapiens	32-44
25593505-11	2014	Treatment of the cells with the beta-catenin inhibitor XAV939 resulted in decreased expression of nuclear beta-catenin, VEGF levels, pBcl-2, and EMT proteins, as well as increased mitochondrial depolarization.	XAV939	55-61	catenin beta 1	Homo sapiens	106-118
25593505-11	2014	Treatment of the cells with the beta-catenin inhibitor XAV939 resulted in decreased expression of nuclear beta-catenin, VEGF levels, pBcl-2, and EMT proteins, as well as increased mitochondrial depolarization.	XAV939	55-61	vascular endothelial growth factor A	Homo sapiens	120-124
24914950-7	2014	Modulation of these mTOR and Wnt pathway proteins was also prevented by combination treatment with SU11274, everolimus, an mTOR inhibitor, and XAV939, a Wnt inhibitor.	XAV939	143-149	mechanistic target of rapamycin kinase	Homo sapiens	20-24
25085990-6	2014	In addition, we also analysed the effect of a novel nano-stroma incorporating XAV939 (XAV), a potent inhibitor of the developmentally important Wnt-beta-catenin signalling pathway, to investigate whether it could also promote the survival and differentiation of human fetal dopaminergic precursors; we found that the numbers of both tyrosine-hydroxylase-positive neurons (a marker of dopaminergic neurons) and total neurons were increased.	XAV939	78-84	catenin beta 1	Homo sapiens	148-160
24861203-5	2014	In this study, we found that XAV939, a small-molecular inhibitor that stimulated beta-catenin degradation by stabilizing axin, protected against serum and glucose deprivation (SGD)-induced cell death in oligodentrocyte cell line OLN-93 cells in a concentration-dependent manner.	XAV939	29-35	catenin beta 1	Rattus norvegicus	81-93
24861203-6	2014	We further showed that XAV939 reduced caspase-3 and caspase-8 levels and increased the expression of phosphorylated Akt in SGD-induced OLN-93 cells.	XAV939	23-29	caspase 3	Rattus norvegicus	38-47
24861203-6	2014	We further showed that XAV939 reduced caspase-3 and caspase-8 levels and increased the expression of phosphorylated Akt in SGD-induced OLN-93 cells.	XAV939	23-29	caspase 8	Rattus norvegicus	52-61
24861203-6	2014	We further showed that XAV939 reduced caspase-3 and caspase-8 levels and increased the expression of phosphorylated Akt in SGD-induced OLN-93 cells.	XAV939	23-29	AKT serine/threonine kinase 1	Rattus norvegicus	116-119
25190315-4	2014	XAV939 is a small-molecule inhibitor of TNKS1.	XAV939	0-6	tankyrase	Homo sapiens	40-45
24898581-4	2014	Our results demonstrated that XAV939 significantly inhibited the activation of Wnt/beta-catenin signaling and attenuated bleomycin-induced lung fibrosis in mice, and thus improved the survival of mice with lung injury.	XAV939	30-36	catenin (cadherin associated protein), beta 1	Mus musculus	83-95
23752181-5	2014	Furthermore, inhibition of the Wnt/beta-catenin pathway by XAV939 negated the effect of EphA2 overexpression, whereas activation of the Wnt/beta-catenin pathway by LiCl impaired the effect of the EphA2 knockdown on EMT.	XAV939	59-65	catenin beta 1	Homo sapiens	35-47
24054872-11	2014	We show that the tankyrase inhibitor XAV939 (which promotes beta-catenin degradation) reduced androgen-independent LNCaP-AI cell line growth compared with androgen-responsive LNCaP cells via an accumulation of cell proportions in the G0/G1 phase and reduction in the S and G2/M phases.	XAV939	37-43	tankyrase	Homo sapiens	17-26
24054872-11	2014	We show that the tankyrase inhibitor XAV939 (which promotes beta-catenin degradation) reduced androgen-independent LNCaP-AI cell line growth compared with androgen-responsive LNCaP cells via an accumulation of cell proportions in the G0/G1 phase and reduction in the S and G2/M phases.	XAV939	37-43	catenin beta 1	Homo sapiens	60-72
24789807-4	2014	XAV939 is a small molecule inhibitor of TNKS1 and can induce apoptosis of NB cells.	XAV939	0-6	tankyrase	Homo sapiens	40-45
24789807-8	2014	These findings suggest that XAV939 treatment or RNAi-TNKS1 inhibits the stemness and migration of NB CSCs via the repression of TNKS1, and TNKS1 may be a potential molecular target for eliminating NB CSCs by small molecule drugs.	XAV939	28-34	tankyrase	Homo sapiens	128-133
24789807-8	2014	These findings suggest that XAV939 treatment or RNAi-TNKS1 inhibits the stemness and migration of NB CSCs via the repression of TNKS1, and TNKS1 may be a potential molecular target for eliminating NB CSCs by small molecule drugs.	XAV939	28-34	tankyrase	Homo sapiens	128-133
23873022-9	2014	Furthermore, treatment with XAV939 selectively inhibited beta-catenin-mediated transcription and Testican-1-induced EMT signaling, leading to G1 arrest.	XAV939	28-34	catenin beta 1	Homo sapiens	57-69
23873022-9	2014	Furthermore, treatment with XAV939 selectively inhibited beta-catenin-mediated transcription and Testican-1-induced EMT signaling, leading to G1 arrest.	XAV939	28-34	SPARC (osteonectin), cwcv and kazal like domains proteoglycan 1	Homo sapiens	97-107
23622245-8	2013	Inhibition of TNKS by either RNAi or a small-molecule inhibitor, XAV939, blocks this process to reduce 26S assembly.	XAV939	65-71	tankyrase	Homo sapiens	14-18
24361264-5	2014	We then tested the effect of intrathecal administration of XAV939, a Wnt/beta-catenin signaling inhibitor, and found that this treatment effectively attenuated the induction of neuropathic pain.	XAV939	59-65	catenin beta 1	Homo sapiens	73-85
24900625-3	2013	A set of 2-arylquinazolin-4-ones has been designed and identified as potent and selective TNKS inhibitors, some being more potent and selective than the lead inhibitor XAV939, with IC50 = 3 nM vs. TNKS-2.	XAV939	168-174	tankyrase	Homo sapiens	90-94
24900625-3	2013	A set of 2-arylquinazolin-4-ones has been designed and identified as potent and selective TNKS inhibitors, some being more potent and selective than the lead inhibitor XAV939, with IC50 = 3 nM vs. TNKS-2.	XAV939	168-174	tankyrase 2	Homo sapiens	197-203
24143235-6	2013	Genetic or pharmacological attenuation of beta-catenin by SiRNA or WP modulators (XAV939 and sulindac sulfide) and pharmacological mimicking of PTEN following LY294002 treatment downregulated MMP7 levels as well as enzymatic function of the secreted MMP7 in MMP7 positive PTEN-null TNBC cells.	XAV939	82-88	catenin beta 1	Homo sapiens	42-54
24122419-8	2014	XAV939, a small molecule inhibitor of the Wnt-beta-catenin pathway, suppressed Foxc2-mediated regulation of BMSC differentiation.	XAV939	0-6	LOC100125986	Oryctolagus cuniculus	46-58
24308762-4	2013	XAV939 is a small molecule inhibitor of tankyrase 1(TNKS1).	XAV939	0-6	tankyrase	Homo sapiens	40-51
24308762-4	2013	XAV939 is a small molecule inhibitor of tankyrase 1(TNKS1).	XAV939	0-6	tankyrase	Homo sapiens	52-57
23043088-11	2012	ICG-001 and XAV939, inhibitors of the WNT/beta-catenin pathway, reduced the proliferative effect of miR-154.	XAV939	12-18	catenin beta 1	Homo sapiens	42-54
24335169-11	2013	Conversely, the inhibition of Wnt signaling with tankyrase inhibitor XAV939 results in a decrease in GFP signal of the fusion proteins, while these small molecules have no significant effects on the mutant destruction domain-GFP fusion protein.	XAV939	69-75	Wnt family member 1	Homo sapiens	30-33
24335169-11	2013	Conversely, the inhibition of Wnt signaling with tankyrase inhibitor XAV939 results in a decrease in GFP signal of the fusion proteins, while these small molecules have no significant effects on the mutant destruction domain-GFP fusion protein.	XAV939	69-75	tankyrase	Homo sapiens	49-58
23043088-11	2012	ICG-001 and XAV939, inhibitors of the WNT/beta-catenin pathway, reduced the proliferative effect of miR-154.	XAV939	12-18	microRNA 154	Homo sapiens	100-107
22642687-6	2012	The inhibition of beta-catenin signaling by XAV and NOTCH signaling by DAPT reversed CHIR impact on hiPSC-NPs proliferation.	XAV939	44-47	catenin beta 1	Homo sapiens	18-30
22013039-10	2012	Moreover, XAV939, an inhibitor of tankyrase PARP activity, decreased viral titers to 2 to 5% of control values.	XAV939	10-16	poly(ADP-ribose) polymerase 1	Homo sapiens	44-48
22610277-6	2012	This resistance is reversed by XAV-939, an inhibitor of Wnt-beta-catenin signaling.	XAV939	31-38	catenin beta 1	Homo sapiens	60-72
21706018-6	2011	The small molecule inhibitor XAV939, which targets the enzymatic activity of tankyrase, acted to stabilize Axin2 levels in OLPs from brain and spinal cord and accelerated their differentiation and myelination after hypoxic and demyelinating injury.	XAV939	29-35	tankyrase	Homo sapiens	77-86
21706018-6	2011	The small molecule inhibitor XAV939, which targets the enzymatic activity of tankyrase, acted to stabilize Axin2 levels in OLPs from brain and spinal cord and accelerated their differentiation and myelination after hypoxic and demyelinating injury.	XAV939	29-35	axin 2	Homo sapiens	107-112
20565110-3	2010	The complex of TNKS2 with the potent inhibitor XAV939 provides insights into the molecular basis of the strong interaction and suggests routes for further development of tankyrase inhibitors.	XAV939	47-53	tankyrase 2	Homo sapiens	15-20
20565110-3	2010	The complex of TNKS2 with the potent inhibitor XAV939 provides insights into the molecular basis of the strong interaction and suggests routes for further development of tankyrase inhibitors.	XAV939	47-53	tankyrase	Homo sapiens	170-179